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ABSTRACT 
The prevalence of poor peripheral nerve function increases with age from approximately 8% at 
ages 40-49 to 35% after age 80 and likely contributes to declines in muscle strength, power, and 
mobility limitations. However, longitudinal evidence for the association is lacking and the 
relationship between nerve function and muscle power has not been examined even at a cross-
sectional level. This dissertation investigates the role of sensory and motor peripheral nerve 
function in muscle function decline and incident mobility limitation in older adults using data 
from two longitudinal cohort studies. Data from the Osteoporotic Fractures in Men Study 
(MrOS) show that poor motor and sensory nerve function are independently associated with poor 
muscle power and that light monofilament insensitivity is associated with greater decline in 
muscle power. Findings from the Health Aging and Body Composition (Health ABC) Study 
indicate that sensory and motor nerve function are predictive of subsequent strength and 
concurrent change in strength, although improvement in nerve function may not always lead to 
improvements in strength. We also found that sex modified the relationship between nerve 
function and strength, with motor and sensory nerve function being associated with strength in 
women and only sensory nerve function being associated with strength in men. Additionally in 
the Health ABC Study, we found that poor initial motor and sensory nerve function and 
sustained poor motor nerve function over seven years independently predicted incident mobility 
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iv 
limitation. Understanding the role of neuromuscular parameters in the disablement process may 
help to identify multiple points of intervention. Our findings have important public health 
implications, suggesting a need for future work to examine early prevention of modifiable risk 
factors and secondary prevention to slow muscle function declines and prevent mobility 
limitation. Since our results persisted after adjustment for known risk factors for poor nerve 
function such as diabetes and vitamin B12 deficiency, novel risk factors should also be explored. 
v 
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1.0  INTRODUCTION 
1.1 THE EPIDEMIOLOGY AND PUBLIC HEALTH CONSEQUENCES OF 
NEUROMUSCULAR IMPAIRMENT AND DISABILITY IN LATE LIFE  
The U.S. population is getting older, both the number of older adults and the percentage of the 
population that they make up are increasing at a rapid rate.3 Due to this population shift, it is 
imperative that we identify ways to decrease disability and increase independence in late-life. 
Late-life disability is a major public health issue with severe economic and social consequences. 
Approximately 20% of older adults suffer chronic disabilities4 and over one third of the elderly 
population has some limitation in functional mobility.5  The health care costs for older disabled 
persons are, on average, three times that of nondisabled elderly,6 with the medical expenditures 
for disabled elders reaching $135 billion in 2004.7 In addition, late-life disability has an 
important impact on mortality, morbidity, quality of life and caregiver burden.7,8 As the elderly 
population is expected to double by 2040, comprising one third of the population,7 understanding 
the disablement pathway, risk factors for disability, and potential interventions is a major 
priority.  
While a number of risk factors for disability in late-life have been identified, 
neuromuscular impairment is believed to play a key role. Figure 1.1 depicts a conceptual model 
for neuromuscular impairment’s role in the disablement pathway. This conceptual model has 
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drawn from and expanded upon previously proposed models,9-11 to include important disease and 
lifestyle risk factors such as diabetes, peripheral arterial disease, nutritional deficiencies, and 
decreased physical activity.  These preventable lifestyle and disease-related risk factors play a 
role in nerve dysfunction and/or sarcopenia, leading to diminished muscle function parameters 
such as strength and power, which can progress to functional limitations and ultimately lead to 
disability.  Nerve dysfunction may also act through other pathways, some unknown and some 
proposed, such as reduced proprioception or position sense,12,13 leading to poor physical function 
and disability. Some of these relationships have been investigated in the literature at least at a 
cross-sectional level, indicated by a solid line, while some have not, indicated with a dashed line.  
This model attempts to address a major limitation of previously proposed models by depicting 
the circular nature of functional decline, where decreased muscle function can lead to functional 
limitations, and disability, which can feed back into risk factors such as reduced physical 
activity.  The two way arrow between disability and functional limitations also illustrates the 
potential for transition into and out of disability that commonly occurs in late-life.14,15  It is 
crucial to recognize the potential for recovery from disability, particularly when considering 
possible interventions for older adults, since a major goal of disability research is to design 
effective interventions for prevention and recovery from disability.  This simplified model 
focuses on neuromuscular impairment and does not include other sources of disability, such as 
cognitive function, which also plays an important role in mobility disability.16-18  While this 
model recognizes the importance of the central nervous system,19 its main focus is on declines in 
the periphery, specifically nerve dysfunction, and decreased muscle function (strength and 
power), since the lower-extremity functional limitations strongly and independently predict 
disability.8  
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 1.1.1 Incidence and prevalence of impaired peripheral nerve function with age 
An important risk factor within the causal pathway to disability is impaired nerve function, 
which is associated with diminished lower extremity function in older adults.20,21  The Italian 
Longitudinal Study on Aging (ILSA), which used a comprehensive two-phase screening process 
to identify individuals with distal symmetrical neuropathy (DSN), revealed that DSN is common 
for both diabetic and nondiabetic older adults.22  The first phase assessed self-reported 
symptoms, previous diagnosis, self-reported drugs, and performed a brief neurologic exam. 
Those who screened positive during the first phase underwent a clinical workup with an 
extensive neurologic exam, medical history, and a review of medical records to confirm the 
presence of DSN. Diabetes was similarly assessed with self-report, physician diagnosis, and a 
fasting glycaemia ≥ 140mg/dL. Participants with a fasting glycaemia ≥ 140mg/dL, without a 
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Figure 1.1. Neuromuscular impairment and the disablement pathway 
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positive history, were considered positive only if their glycaemia levels were confirmed with a 
second blood test. The incidence of DSN increased steadily in participants with diabetes, from 
13.7 to 48.4 new cases per 1,000 person years, and in those without diabetes, from 4.6 to 8.8 new 
cases per 1,000 person years, among those 65-79 and 80-84 years of age, respectively. The 
prevalence of DSN in individuals with diabetes increased with age until the 75-79 age group, 
whereas the prevalence in individuals without diabetes continued to increase throughout all the 
age groups. While some of this difference is likely due to a survival effect, it also may suggest 
that although diabetes is an important risk factors for these neuropathies, age or age-related 
factors may become increasingly important in all. 
Data from the National Health and Nutrition Survey (NHANES) also show a high 
prevalence of poor sensory nerve function in adults over 40 years of age in the United States 
among those with and without diabetes at 28.5% and 13.3%, respectively and an increase in 
prevalence with age from 8.1% at ages 40-49 to 34.7% after age 80.23 Diabetes was defined as 
history of physician diagnosis. Due to the use of less sensitive screening measures limited to 
sensory nerve function (10-g monofilament detection and self-reported symptoms) this is likely 
an underestimate of nerve dysfunction in the population.  Critically, the majority of these 
participants were asymptomatic, despite the 10-g monofilament’s high specificity for detecting 
neuropathy.24  Similarly, ILSA found that 85% of DSN cases were undiagnosed.25  Although not 
reported, the rate of undiagnosed cases is likely to be even higher in older adults without 
diabetes, since they are less likely to be screened. These studies demonstrate that poor peripheral 
nerve function is common in older adults, increases with age and that many may be unaware of 
their impaired status, even at a level of dysfunction detectable by clinical screening. 
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The prevalence and incidence of impaired nerve function among different subgroups in 
old age is understudied. While ILSA found that DSN prevalence did not differ among men and 
women, the study was limited to a homogenous population of white Italian elderly from one 
region.25  Data from NHANES shows that rates of poor nerve function were higher in men 
compared to women (18.2% vs. 12.6%, p<0.05) and in non-Hispanic blacks and Mexican 
Americans compared to non-Hispanic whites (21.9% and 19.4% vs. 14.4%, p<0.05); however, 
since these comparisons were not separated by age, little is known about demographic trends for 
poor nerve function in older adults.  Some of the differences in these groups are likely accounted 
for by differences in disease-related factors. This will be discussed further in section 1.6.8.  
1.1.2 Mobility-related consequences of reduced nerve function with age 
Poor peripheral nerve function is associated with key mobility-related outcomes in older adults 
such as physical function limitations and impairments26,27 and increased risk of falls.28-30  Using 
data from the Women’s Health and Aging Study (≥ 65 years of age at baseline), Resnick and 
colleagues used vibration perception threshold to categorize participants as having mild, 
moderate and severe peripheral nerve dysfunction.  They found that all levels of dysfunction 
were related to impaired balance and usual and fast-paced walking speeds and that severe 
dysfunction was related to inability to stand from a chair. They also found that impairments 
believed to mediate the relationship between nerve dysfunction and physical function, such as 
strength and position sense, only explained some of the association. Although motor nerve 
function, which was not measured in this study, may be more mediated by strength, rather than 
vibration perception threshold, which is a measure of sensory nerve function. In addition, side by 
side, semi tandem and tandem standing balance was used as a proxy for position sense and they 
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did not test muscle power as a mediator. The Women’s Health and Aging Study includes 
moderately to severely disabled women at baseline, therefore these findings may not be 
generalizable to individuals without impairments.  
Much of the literature on mobility-related consequences of nerve function has been cross-
sectional,20,27,28,31 with the exception of an analysis in a subsample of participants from the 
Italian Longitudinal Study of Aging.32 In 1052 participants (mean age = 71) with normal 
functioning at baseline, Inzitari and colleagues found that signs and symptoms of DSN predicted 
decline in performance. While the screening for DSN was quite comprehensive in this study (see 
section 1.1.1), the adoption of this method by other large epidemiologic studies is unlikely since 
it is time intensive and requires a physician. Because they limited cases to individuals who were 
diagnosed with DSN, they were unable to study the effects of subclinical impairments in 
peripheral nerve function. In addition, consistent with the majority of literature, findings were 
not presented for motor function. Sensory and motor nerves undoubtedly play distinct roles in 
mobility. Peripheral sensory nerves likely contribute through proprioceptive feedback,12  while 
motor nerves likely affect muscle tissue structure33,34 and function.21,35,36 This distinction is 
supported by findings from Strotmeyer and colleagues that show that motor and sensory nerve 
function are related to different physical performance measures in the Health ABC Study (ages 
70-79 at baseline).20  Using a gold-standard method of measurement, they were able to quantify 
impairment in motor nerve function. They also included a subclinical measure of touch sensation 
(1.4-g monofilament) in addition to a standard measure (10-g monofilament) and a continuous 
measure of average vibration detection threshold in order to capture various levels of 
impairment. They found that nerve function is associated with performance, independent of 
diabetes. This finding has clinical relevance, since older adults without diabetes may be less 
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likely to be screened for neuropathy. It also has important implications for future research, 
indicating that studies should include older adults both with and without diabetes and that both 
traditional risk factors, such as diabetes, and novel risk factors should be studied in older adults.  
1.2 DENERVATION AND PATHOPHYSIOLOGY OF MUSCLE AGING 
The number of motor units (or units of single motor neurons and the muscle fibers they 
innervate) decrease with age.37  This linear decrease appears to begin around age 60, which is 
further evidence that neuromuscular impairments may begin to manifest in late-life and are 
driven by age-related changes.  However, the currently available evidence is based on cross-
sectional data; therefore while it suggests a decline with age, longitudinal data to confirm this is 
lacking. 
Older adults may exhibit muscle atrophy and fiber type grouping (identified by 
histochemical staining properties of myosin ATPase)38 resembling that which occurs in 
individuals with peripheral neuropathy, albeit to a varied degree.39,40  With age, a gradual decline 
in muscle mass is thought to result from a reduction in the size and number of muscle fibers. 
These reductions preferentially affect type II fast twitch fibers.41,42  Whereas healthy young 
muscle fibers are characterized by normal size and an even distribution of type I slow-twitch and 
type II fast-twitch muscle fibers (see Table 1.1 for fiber type characteristics), both neuropathic 
and aged muscle fibers are characterized by smaller atrophied fibers and a grouping of type I and 
type II fibers (see Figure 1.2).  This grouping is believed to be a consequence of motor nerve 
death.  When motor nerves die, muscle fibers are denervated, then reinnervated, often switching 
to the fiber type of adjacent living fibers.34,43-46  Since fewer motor neurons cannot innervate all 
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remaining muscle fibers, this denervation may also account for loss in muscle mass43 and decline 
in muscle-specific force.35,36  
A) Young Muscle2 C) Older Sarcopenic
Muscle2 B) NeuropathicMuscle1 
Type II 
Type I 
Figure 1.2. Neuropathic and aging muscle characteristics 
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Table 1.1. Muscle fiber type characteristics 
(for review see Houmard 2000) 
Characteristics Type I Fibers Type IIa Fibers Type IIb or IIx fibers 
Contractile 
properties38 
Slow-twitch - 
Produce low tension 
but have prolonged 
contraction and 
relaxation time 
Can produce more 
tension than type I fibers, 
but also somewhat prone 
to fatigue 
Fast-twitch – 
Fatigue prone but produce 
the highest amount of 
tension 
Energy 
production38 
Primarily rely on 
oxidative pathways 
Have almost as much 
oxidative ability as Type 
I fibers, but also produce 
substantial energy 
through the glycolytic 
pathway 
Mostly rely on non-
oxidative, glycolytic 
pathways 
Age related 
changes47 
Transition to a 
higher percentage of 
these with age 
Relative contribution to force and power believed to 
decline with age 
Distribution in 
the body38 
Account for 
approximately 50% 
of all fibers in the 
average person 
Endurance runners 
typically greater 
percentage38 
Account for approximately 50% of all fibers in the 
average person 
Can account for 80-90% in sprinters38 
Conditions such as hypothyroidism,48-50 chronic heart 
failure,51 and obesity with non-insulin dependent 
diabetes52-55 can lead to an increased expression 
Transition from these to 
type I fibers is 
controversial and may 
take many years of 
intense training56 
Predominant in those 
sedentary individuals due 
to inefficient contractile 
properties57 
Fewer percentage in 
trained athletes55 
Transition from these to IIa 
may take as little as 6-8 
weeks of training in 
healthy younger and older 
(ages 60-70) men and 
women49,55,56 
9 
To characterize and quantify the relationship between nerve function and declines in 
muscle with age, objective and reliable assessments of nerve function, such as nerve conduction 
(NC) studies,58-61  are needed.  NC studies are the most sensitive and specific method to detect 
peripheral neuropathy non-invasively.62  They are performed by electrically stimulating a nerve 
and measuring the response using surface electrodes.  NC study measures include compound 
muscle action potential (CMAP) and sensory nerve action potential (SNAP) amplitude, the size 
of an evoked response from electrical stimulation of the nerve, and nerve conduction velocity 
(NCV), the speed at which the response travels down the nerve.  Decreases in CMAP amplitude 
may be indicative of axonal damage, whereas decreases in NCV may indicate damage to the 
myelin sheath, which insulates the axon.63  Latency, or the travel time of the signal, is sometimes 
used in place of NCV. The value of NCV is dependent on the method used to calculate NCV.64 
Nerve conduction velocity is typically calculated by dividing the distance between two 
stimulation sites by the difference between latencies.65 Using the difference between two 
stimulation sites accounts for the variability of travel time that can occur within the 
neuromuscular junction. In the case that only one latency is available, it can be used on its own 
or to estimate nerve conduction velocity. Although, NCV takes into account the length of the 
limb, and thus the distance travelled by the signal, and has established clinical cut points for 
certain conditions, such as diabetic polyneuropathy,66 whereas latency does not. 
Decline in peroneal motor amplitude, but not NCV, with age has been independently 
associated with declines in calf muscle density,33 a measure of muscle-fat infiltration and 
intracellular fat content in muscle.67  Interestingly, these NC parameters were not associated with 
muscle cross-sectional area, suggesting that the effects of PN on muscle may not be detected as 
macroscopic changes in muscle mass, but as changes in muscle tissue structure.  Moreover, these 
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relationships may be independent of traditional risk factors, since associations remained when 
excluding participants with DM and PAD.  However, since these associations have only been 
studied cross-sectionally, longitudinal data is needed to identify temporal relationships and 
causation.  
1.3 MUSCLE FUNCTION CONSEQUENCES OF NEUROMUSCULAR AGING 
Age-related changes in muscle structure and nerve function are accompanied by declines in 
muscle function.  Two distinct measures of muscle function are muscle strength, or the 
maximum force that can be generated during muscle contraction, and muscle power, defined as 
the product of contractile force and the velocity of movement.  Both strength and power decline 
with age although decline in power is steeper,68-70 suggesting that power may be an earlier 
indicator of functional decline.  
Decline in muscle function with age is likely due to a number of neuromuscular changes. 
Loss of muscle mass is closely associated with declines in strength; although, longitudinal 
decline in strength has been shown to occur three times more steeply with age than mass.10,71,72 
Furthermore, maintaining or gaining muscle mass does not fully prevent the decline in strength 
that occurs with age.71  Similarly, training programs may increase strength prior to the 
occurrence of observable changes in muscle structure (See  Gabriel, 2006 for review).73  Some 
evidence from physical therapy research suggests that these early increases in strength may result 
from alterations within motor units and the central nervous system.73  Strength gains occurring 
during early phases of training prior to increases in muscle size have been associated with 
increased amplitude measured using surface electromyography (EMG).73 This increase in 
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amplitude has been commonly interpreted as an increase in neural drive, although this 
measurement technique does not provide an isolated measure of nerve function, but a more 
global measure of neuromuscular activity (see Table 1.2 comparing EMG and NC studies).  An 
increase in motor unit firing rate during maximal voluntary contraction (MVC) has also been 
observed in as early as the first 48 hours following training.73,74 
Table 1.2. Nerve conduction (NC) studies and electromyography (EMG)74 
Nerve Conduction Studies Electromyography 
Purpose Used to measure neurodegeneration. 
Used clinically as a sensitive and 
specific method to detect peripheral 
neuropathy,62 carpal tunnel, Guillain-
Barre syndorme, 
facioscapulohumeral muscular 
dystrophy, spinal disc herniation, 
Guyon Canal syndrome.  
Used in the kinesiologic analysis of muscle 
and in biofeedback studies. 
Used clinically to study anterior horn cell, 
nerve root, plexus, peripheral nerve, and 
primary muscle disorders. Can be used to 
estimate time since onset and severity of 
axonal injury.  Limited use in purely 
demyelinating neuropathies, since axons 
and connections with muscle fibers remain 
intact.75 
Methods Performed by electrically stimulating 
a nerve and recording the signal at 
the muscle supplied by that nerve 
with a surface electrode. 
Performed by recording the 
electrophysiological activity when the 
motor unit is at rest or during a muscle 
contraction using either a needle electrode 
inserted into the leg or a surface electrode. 
Measures 
obtained 
The amplitude and speed of an 
electrical signal transmitted across a 
stimulated nerve.  
Assesses nerve function separately 
from the muscle.  
Records the summated compound 
potential of many motor units. 
Electrical potential generated by muscle 
cells when the cells are activated by the 
nerve (either when the motor unit is at rest 
or during muscle contraction) or an applied 
electrical stimulation. 
Assesses the nerve and muscle fibers that it 
innervates at the same time (the entire motor 
unit). 
Spontaneous activity and activity from an 
individual motor unit can be measured 
within the muscle using needle electrodes. 
12 
Measures from NC studies have been associated with muscle strength in older adults. In a 
cross-sectional analysis of community dwelling older adults from the Health ABC study (ages 
70-79 at baseline), Strotmeyer and colleagues found that measures of poor sensorimotor nerve 
function, including low peroneal motor nerve amplitude, and impaired monofilament and 
vibration threshold detection, contributed to lower quadriceps and ankle strength.21 Peroneal 
motor nerve conduction velocity (NCV), however, was not related to strength.  One proposed 
explanation for this is that a proportion of axons may degenerate in late-life resulting in reduced 
motor amplitude, while NCV, driven by the axons that remain intact, may stay within normal 
limits; in this case, even though NCV is normal, decreased amplitude still results in a weaker 
muscle response.33,76 These associations were independent of diabetes and lean mass, although 
they were not adjusted for measures of muscle composition, such as muscle density or 
intermuscular adipose tissue (IMAT).  Previously, these authors found that poor nerve function 
was related to worse physical performance.20 Nerve function attenuated the relationship between 
quadriceps strength and performance battery scores by 13%, suggesting that it may play an 
important role in the relationship between decline in muscle function and mobility impairments.  
It is notable that sensory nerve measures (monofilament and vibration threshold detection) were 
also related to diminished strength.  This is not surprising, since the absence afferent (sensory) 
feedback is related to poor motor nerve performance in patients with severe sensory deficits.13,77  
Additionally, the importance of afferent proprioceptive input on physical function has been 
previously demonstrated.78,79  Longitudinal analyses are needed to investigate the role of nerve 
function in declining strength and physical function in late life. Moreover, similar research 
examining the connection between muscle power and NC measures are lacking, despite the 
hypothesized neural contribution to power.  
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Studies on the link between neuromuscular activation measured using EMG and muscle 
strength and power in older adults have produced somewhat conflicting findings. Early cross-
sectional studies comparing small groups of healthy older (ages 73-91) to healthy younger adults 
(ages 19-55) have found that older adults experience lower strength, despite being able to fully 
activate their muscles.80,81 Similarly, compared to young (ages 19-33)82 and middle aged (ages 
44-57)83 adults, healthy older adults (ages 59-7483 and 60-6982) had lower muscle power and 
explosive force without any differences in EMG nerve activity.82,83  However, mobility limited 
older adults (ages 70-85) exhibited lower muscle power accompanied by diminished EMG 
activity when compared to both healthy older (ages 70-85) and younger groups (ages 40-55).84  
This EMG activity was correlated with the velocity component of muscle power across all 
groups, suggesting that neuromuscular activation plays a key role in muscle contractile velocity.  
A potential explanation for the discrepancy in these findings is that the progressive loss of motor 
units with aging may not lead to functional impairments until a critical threshold is reached.85  
Until this threshold is reached, the function of muscle fibers may be maintained through 
collateral reinnervation in the early stages of motor unit loss. A critical threshold for the tibialis 
anterior may occur, between 70-80 years of age, when the number of motor units is 50% of that 
found in younger, healthy adults.  Decline in motor units is likely muscle-specific and age-
threshold dependent (e.g. increased rate of decline in motor units may occur at an older age for 
the soleus than for the anterior tibial muscle),86 which may be related to differences in fiber-type 
composition or adaptation of muscle activity patterns of movement with age.  Therefore, more 
research is needed to help identify potential critical thresholds in other muscles.  
Methodological limitations in these studies need to be addressed.  Firstly, they included 
small sample sizes (n=10-32 per group); therefore, the lack of associations observed could be 
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due to limited statistical power.  They only collected cross-sectional data, providing no evidence 
for any causal direction of association. Furthermore, a standardized protocol was not used for 
either power (discussed further in section 1.5.1) or EMG measurement. Different measurement 
protocols could lead to variation in outcomes and conflicting findings on whether an association 
exists.  In addition, EMG provides an overall measure of the whole motor unit rather than an 
isolated measure of nerve function (See Table 1.2 for EMG characteristics). 
To what extent neuromuscular structural changes and functional declines are inevitable 
with age is unclear.  While muscle atrophy with age is consistently observed across studies,38 
findings on fiber type conversion are conflicting.43,87-90  Structural changes in muscle with age 
may be somewhat sex specific. Whereas both type I and type II fiber area decline with age in 
women,91 a preservation of type I fiber area has been observed in men.43,87-89  Resistance training 
has been found to be effective for improving muscle function (see section 1.7 on training 
interventions) and structure in older adults,92-95 although evidence suggests that it cannot 
completely reverse the impact of the aging process.90  Small studies have found that physical 
activity may improve or reduce loss of peripheral nerve function in diabetic and peripheral 
neuropathy patients; however no clinical trials have been done to examine the effects on age-
related peripheral nerve declines.96-98  Potential mechanisms by which exercise training could 
prevent or treat peripheral nerve decline include improvements in glycemic control99 and 
vasculature (for review see Tasfaye et al., 2005100). It is also possible that exercise could have 
direct and local effects on peripheral nerves (e.g. improvements in Na/K ATPase activity).96 In 
addition, specificity of training could potentially lead to physical function improvements that 
allow those with peripheral nerve impairments to compensate through improved strength, power, 
and/or balance. More research is needed on the extent to which specificity, intensity, and volume 
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of training can prevent or mitigate structural and functional neuromuscular declines that occur 
with age. One important area to investigate is the relative benefits of short term specific training 
exercises vs. general sustained activity, since this could have important consequences for 
designing interventions to preserve physical function in older adults.  
1.3.1 Sex trends in neuromuscular parameters with age 
Compared to men, women have higher rates of disability101-103 and falls in old age.104,105  
Differences in neuromuscular parameters may play a key role in these late-life disparities.  
Although muscle strength and quality declines more steeply with age in men,106 they tend to have 
significantly more muscle mass, strength, power, and velocity70,107-109 than women throughout 
life.  During a maximal counter-movement jump, the difference in muscle power was most 
pronounced during the end of the concentric phase.108  The majority of this difference in power 
was attributed to the velocity component during this phase of the jump.  This discrepancy could 
contribute to women being more prone to falls in old age.  Recovery of balance from a potential 
fall requires rapid movement.  A small study of younger (ages 21-29) and older (ages 67-81) 
men and women showed that older women were less likely to recover balance from a fall by 
taking a single rapid step.110  In addition, power may explain more of the variance in 
performance measures, such as chair rises, stair climbing and walking in women than in men.109  
Reasons for these differences between men and women are not fully understood, 
although the additional muscle mass and preservation of type I fiber area with age in men43,87-89 
may play a role.  Differences in nerve parameters may also occur by sex.  Men tend to have 
slower nerve conduction velocity, which is primarily due to greater height;111  although estrogen 
may have some neuroprotective effects,112 at least at the level of the brain. Men also have 
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reduced neural activation,113  commonly defined as the recruitment and rate coding of motor 
units to generate force through muscle contraction and is measured using EMG.114  The direction 
of this difference in nerve parameters may seem counterintuitive, but reduced neural drive has 
been associated with lower eccentric/concentric ratios, which is a proposed mechanism for injury 
prevention during activities where muscle fiber tension is high (for review see Stauber et al., 
1989).115  Single muscle fiber quality measures, including fiber size, maximal isometric and 
specific force, maximal unloaded shortening velocity, power, and specific power, are likely not 
contributing factors since they have not been found to differ by sex.107  Research on these gender 
disparities in neuromuscular parameters, are not only crucial due to their potential consequences 
for function, disability, and maintaining independence in old age, but may also provide insight 
into potential kinematic and physiologic mechanisms for these key outcomes.  
1.4 SARCOPENIA AND DYNAPENIA 
Sarcopenia, defined as loss of muscle mass with age,116,117 is associated with functional 
impairment,118,119 disability,120,121 falls,122 and loss of independence.123    More recent definitions 
of sarcopenia have included loss of strength, 124-127  likely due to its association with poor 
outcomes, independent of lean mass.9  In 2001, it was estimated to contribute to $18.2 billion in 
healthcare costs.128  Potential risk factors for sarcopenia include nutritional deficiencies, chronic 
disease, insulin resistance, inflammation, change in endocrine function, and inactivity,125 
although age-related declines in muscle mass can even be observed in fit, athletic older adults.129 
One major proposed mechanism for this age-related decline in muscle mass is a withdrawal of 
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anabolic stimuli to skeletal muscle, such as the continuous activity of motor neurons, leaving 
catabolic processes unopposed.33  
The prevalence130 of sarcopenia increases with age, however, estimations depend on the 
definition and method of measurement used.  Loss of muscle mass is most precisely quantified 
using advanced imaging techniques such as dual-energy x-ray absorptiometry (DXA), computed 
tomography (CT), and magnetic resonance imaging (MRI).126,131-134  In the absence of advanced 
imaging technology, lower-tech substitutions such as calf and mid arm circumference135  and 
bioelectrical impedance136 can be used, albeit with less accurate and reliable results.  Once a 
measure of lean mass is obtained, it is used to produce an index, taking into account height, 
weight, BMI, or fat mass.137-139  The Health, Aging, and Body Composition (Health ABC) Study 
directly demonstrated the effects of using different methodologies for estimating the prevalence 
of sarcopenia in a single study population of adults ages 70 to 79 years.138,139  The first method 
used appendicular lean mass measured by DXA and divided it by height-squared (LM/ht2).  For 
the second method, they adjusted their measure of lean mass by height and fat mass (the residual 
method).  Using both the residual and the LM/ht2 methods, baseline rates for an age range of 70-
79 years were highest in white women (30.5% and 31.4%), followed by white men (27.1% and 
25.2%), then black men (8.2% and 11.8%) and finally black women (8.1% and 6.8%).  However, 
the residual method resulted in higher rates for obese men and women (11.5 and 21.0% vs. 0% 
for both using the LM/ht2 method)138 and was more strongly related to poor lower extremity 
function.138,139  
While some definitions of sarcopenia include declines in strength, Manini and Clark 
proposed using a separate term, dynapenia, to describe loss of muscle function, since factors 
other than muscle mass also contribute to this decline.9,10  Figure 1.3 shows their theoretical 
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model illustrating potential neuromuscular parameters as mechanisms for the occurrence of 
dynapenia with age.  The top of the model shows spinal characteristics and the neuropathic 
processes leading to changes in motor unit recruitment and discharge rate.  At the bottom, 
pathophysiologic parameters, such as excitation-contraction uncoupling, fiber type 
transformation and architectural changes, may lead to a decline in contractile quality.  It also 
includes lifestyle factors such as a decrease in protein intake and decline in physical activity that 
can lead to sarcopenia.  Factors that act on both the nervous system and muscular system sides, 
such as hormonal and immunologic changes, peripheral input, and neuropathic processes that can 
lead to structural changes in the muscle are also included.  Major limitations of this model 
include that it does not include disease-related risk factors or recognize the unique contributions 
of muscle power. 
 
Figure 1.3. Etiology of the age-associated loss of strength (dynapenia)* 
*Reproduced from Clark and Manini, 201210 
 19 
1.5 MUSCLE POWER VS. MUSCLE STRENGTH 
The relationship between nerve function and muscle power may be distinct from the relationship 
between nerve function and muscle strength.  Table 1.3 outlines some important differences 
between strength and power.  Power declines more steeply with age than strength69,70 and is more 
strongly related to certain measures of physical function.140-143 The distinct relationship between 
physical function and declines in power is likely due to the diminishment of contractile velocity, 
the distinguishing component of power, which is also associated with physical function 
impairments.144  While it has been suggested that decline in power and its unique relationship 
with mobility may be in part due to loss of type II (fast twitch) muscle fibers and decline in 
peripheral nerve function,2,41,74,144-146 more work is needed to elucidate the mechanisms 
responsible for the decline in muscle contractile velocity with age.  Recruitment and discharge 
rate of motor neurons are also likely to play an important role. 
Strength and power distinctly contribute to poor physical function with age,140-142,147-150 
although few studies have been able to fully distinguish the independent roles that strength and 
power play in different measures of physical function. Table 1.3 integrates the findings from a 
number of studies in an attempt to summarize these relationships.  A major limitation of the 
literature is that few studies have statistically compared the relationship of strength vs. power 
with physical function measures. However, based on magnitude of R2 and correlation 
coefficients, power may be more strongly related to measures of physical function such as the 6-
minute walk,147,151 the 400m walk,142 time to stand from a chair 10 times,140,147-149 stair climb 
time,140,141,147-149 the tandem walk,140 balance scores,141 the Short Physical Performance Battery 
(SPPB) score,140,141 and timed up and go;147 whereas, strength may be equally or more influential 
on maximal gait speed,140,149 time to stand from a chair one time,147 and the one-leg stand.147 
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There have been conflicting findings in the literature on whether strength or power is more 
influential on habitual gait speed140,141,148,149 and time to stand from a chair five times.141,150 
Given the additional component of velocity of movement that is captured in measures of muscle 
power, it may be expected that power would be more related to performance measures that 
require speed. 
While much of this work has focused on women143,144,148,149 and those with mild to 
moderate functional limitations,140,143,148,149,151,152 few have looked at the oldest old,68 racially 
diverse populations,152,153 or populations of older adults with a wide range of functional abilities. 
Importantly, various methods of measuring muscle power were used in these studies and whether 
the method of power measurement has an effect on its relationship to physical function is 
unknown.  For instance, a pneumatic leg press machine such as the Keiser (Fresno, CA) allows 
power to be measured at varied percentages of the participant’s one repetition maximum (1 RM, 
or the maximum amount of resistance that they can push before failure).  As opposed to strength, 
which has a linear relationship with resistance, muscle power has a J-shaped relationship with 
resistance.154  At very low resistances, the force component of power is minimized, resulting in 
low power.  Conversely, very high resistances result in low velocity and therefore low power.  
Power peaks when resistance is high enough generate a large force, yet low enough to allow for 
fast velocity of movement. Different physical function tasks may be associated with muscle 
power production at varying force-velocity ratios.141  Moreover, task-based measures of muscle 
power, which use the participant’s own body weight as resistance, could potentially be more 
related to certain measures of physical function since they may mimic everyday tasks such as 
rising from a sitting position or climbing stairs, although this has not been assessed. 
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Strength and power cut points for mobility limitations have also been examined. Using 
data from the Health ABC study (ages 70-79), Manini and colleagues identified strength cut 
points by dividing strength into sex-specific deciles and using Cox proportional hazard 
regression to compare change in risk of developing severe persistent mobility limitations, 
defined as two consecutive reports of a lot of difficulty or inability to walk ¼ mile or climb 10 
steps.155  They found that strength < 1.13 Nm/kg (the first decile) for men and < 1.01 Nm/kg (the 
third decile) for women were associated with high risk of developing mobility limitation. Cut 
points for low, moderate, and high risk significantly predicted mobility limitation, gait speed 
<1.22 m/s, and death.  However, given that these cut points were identified in an initially healthy 
population with no mobility disability at baseline, they may not be generalizable to other 
populations of older adults.  In addition, they did not assess whether strength loss predicted 
disability. 
Similarly, using data from the InCHIANTI study (ages 65-102), Hicks and colleagues 
identified sex-specific cut points for strength and power for predicting mobility limitation.156  
Men with knee extension strength <19.2 kg and grip strength <39.0 kg had clinically meaningful 
decline in gait speed157 of 0.24 m/s over three years. While they did not present these results in 
quantiles to compare across different ranges of magnitude, these correspond to 3.2 and 3.8 
standard deviations (SD) of strength, respectively. Men with power <105 W (1.7 SD) 
(unilaterally on power rig) were nine times more likely to develop incident mobility disability, 
defined as being unable to walk 1 km or climb a flight of stairs. In women knee extension 
strength <18.0 kg (4.3 SD) was associated with minimal gait speed decline of 0.06 m/s, 
suggesting that strength may be a better predictor for mobility disability in men than in women.  
Women with leg power <64 W (1.8 SD) were three times more likely to develop incident 
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mobility disability.  Mobility and disability outcomes were not consistently defined for strength 
and power, since they used the classification and regression tree (CART) method, which 
identifies predictors and cutpoints that have the strongest relationship with outcomes; therefore, 
the authors were unable to compare the effects of strength vs. power directly. They also 
neglected to adjust for potentially important confounders such as body size and comorbid 
conditions. Three year change in strength and power did not predict incident mobility disability.  
However, they did not examine the role of baseline measures in the change model, which is 
important since some individuals may not have experienced much change in strength or power 
because they started out with low levels and had little room for decline.  More research is needed 
to investigate whether strength and power decline over a longer time period predict incident 
mobility disability.  It may also be possible that strength or power may decline concurrently with 
physical function; however this has not been examined. 
In a post-hoc analysis of data from a 16-week intervention designed to increase muscle 
function and improve mobility in older adults (mean age 75.2), changes in power predicted 
clinically meaningful changes in mobility (1 unit in SPPB score and 0.1 m/s in gait speed), while 
changes in strength did not.158  Power remained a significant predictor when strength was added 
into the same model, showing that the association with power was independent of strength. This 
suggests that power is distinctly important for mobility in older adults. 
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Table 1.3. Strength vs. power 
Muscle Strength Muscle Power 
Definitions Force 
Maximum capacity to generate 
force 
Force x Velocity 
Integration of force and velocity of movement 
Maximum rate of work production 
Age trend Declines with age beginning 
around age 40159 
 Declines with age beginning around age 40159 
Declines more steeply than strength (3.5% vs. 1-2% 
per year70)68-70,160  
Relationship with 
muscle mass 
Most of variance is explained by 
muscle mass, but yearly declines 
are 3x greater for strength 
(Goodpaster et al., 2006 JGMS) 
Relationship with 
resistance 
Linear J-shaped154 
Low power at very high resistances due to low 
velocity of movement 
Low power at very low resistances due to low force 
Relationship with 
physical function  
↓ Strength may result in: functional 
impairment, disability, falls and 
loss of independence 
Compared to power, strength may 
be more strongly related to max 
gait speed,140 chair stand 1x, and 
one leg stand 
↓ Power may result in: functional impairment, 
disability, falls and loss of independence 
Compared to strength, power may be more strongly 
related to 400m walk time,142 6-minute walk 
distance,151 SPPB score,140,141 chair stand 10x,140 
tandem walk,140 balance score,141 get up and go, and 
stair climb140,141,148 
Velocity component of power may be more strongly 
related to physical function measures than force 
component144 
Potential mechanism 
for peripheral nerve 
involvement  
Motor unit recruitment 
Muscle atrophy 
Motor unit recruitment and discharge rate 
Muscle atrophy 
Decreased contribution of type II ‘fast-twitch’ fibers 
to force and power generation 
Methods of 
measurement 
Isometric maximal voluntary 
contraction (MVC) – does not 
require movement 
 Dynamic 1 repetition maximum (1 
RM) – can be measured 
isotonically (constant resistance) or 
isokinetically (constant velocity) 
Isokinetic (constant velocity) dynamometer 
Fixed load power rig 
Pneumatic resistance equipment 
Task-based measures using a force plate or scale  
Rate of stair climbing (body weight and stair height 
can be used to estimate power)149,152,161 
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1.5.1 Measuring muscle power in older adults 
Currently, no gold standard method of measuring muscle power in older adults has been 
identified.  Methods vary by equipment, time, and intensity of activity.  Table 1.4 outlines some 
key advantages for certain measures. Each method likely has various strengths and limitations. 
However, few studies have systematically compared more than a few power measures in a single 
study population or assessed feasibility of different power measures for older adults. This has 
important implications characterizing the feasibility of methods in large epidemiologic studies of 
older adults, for designing and evaluating training interventions, and for better understanding 
muscle power’s role in the disablement pathway.  
Power can be measured using specialized equipment, in which the participant is generally 
seated and performs a leg press or knee extension.  An example of this is the Keiser pneumatic 
resistance machine, which uses air pressure to provide a constant resistance during the 
movement. The Keiser has been previously validated against various laboratory and field tests 
designed to assess power such as the leg extensor power rig, the Wingate anaerobic power test, 
and the vertical jump test,162 and is considered to be a reliable and reproducible (r = 0.90, ICC = 
0.85-0.88) measure of lower extremity muscle power.143,148,162-164 First, the participant’s one 
repetitions maximum (1 RM), or the maximum resistance a participant can displace before 
failure, must be established. Following a brief rest, power is then measured at different 
percentages of the 1 RM (generally 40-70%) to find peak power.  During the power test, the 
participant is instructed to press or extend one or both legs as fast as possible through full range 
of motion.  This method provides a separate measure of velocity.  Since this equipment allows 
power to be measured at varying resistances, it may more accurately capture peak power than 
equipment that uses a fixed resistance. Limitations may include relatively long test duration and 
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somewhat high participant burden, since a 1 RM must be establish before power can be 
measured.  This is disadvantageous for a large epidemiologic study of older adults that must 
collect multiple measures and may have limited time before the participant fatigues. 
A fixed load machine such as the Nottingham power rig can also measure leg press 
power and has high reproducibility (coefficient of variation = 9.4%) and validity when compared 
to power measured by an isokinetic dynamometer and two-legged jumps on a force plate 
(rho=0.73, p<0.001; rho=0.86, p<0.001, respectively).165  Similarly, the participant is instructed 
to push one or both pedals as quickly as possible through full range of motion. However, unlike 
pneumatic resistance equipment, a 1 RM does not need to be established. This may be 
advantages for time and participant burden; however, it does not allow power measurement at 
varying resistances. This could potentially cause to ceiling or floor effects. The participant is 
asked to perform until their power plateaus or up to 5-10 trial. Compared to other equipment 
used to measure muscle power, such as the Keiser, which provides additional components such 
as velocity and force, and force plates (discussed in the next paragraph), which provide these 
components as well as additional biomechanical components (e.g. center of mass displacement), 
power is the only measure provided. This allows for easy, yet limited data collection and 
management. This equipment uses a flywheel that is low to the ground and must be manually 
adjusted, which may be difficult for some clinic staff to operate, as experienced by the staff 
University of Pittsburgh (unpublished observation, Dr. Jane Cauley). 
One limitation for the above described measures is that they are not portable and only 
allow measures to be collected in a clinic setting. Novel task-based methods may overcome this 
limitation. In addition, task-based methods, which use the participant’s own body weight as 
resistance, may more closely mimic older adults’ ability to perform tasks essential to 
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independent daily living.  These measures often use a mat or a plate to collect the force 
component of power and calculate the velocity as the vertical acceleration of the center of mass 
over time. An example of a task-based method is rising from a chair as quickly as possible on top 
of a force plated. Jumping (counter movement or squat jumps) on top of a force plate may also 
be used.  Generally, the participant is instructed to jump as high as possible and power is 
measured from the “push off” phase of the jump.  It has been suggested that functional measures 
of leg power may be able to identify decline in muscle function earlier than physical 
performance measures166 and detect greater variability in a high functioning population of older 
adults,167 although this has not been investigated.  In addition, the force plate collects a number 
of data parameters in addition to force and velocity that can more fully characterize the task-
based movement. Some functionally-based measures of leg power have been validated in the 
elderly.  Chair rise and jumping power have shown high test-retest reliability (r = 0.95 and r = 
0.99, respectively) in older adults.152,166  Chair rise power has correlated moderately high with 
the Nottingham power rig (r = 0.6)167 in older adults.  Jumping power was highly correlated with 
the Nottingham power rig (r = 0.67168 and 0.86165) and moderately correlated with chair stand 
power (women: r = 0.58, men: r = 0.61169).  Jumping power declined consistently more with age 
than chair rise power.169  Stair climb power is another example of task-based power, which does 
not require a force plate.  The participant is asked to climb a flight of stairs as quickly as possible 
(using handrails if necessary).  Power is then calculated using the following equation: force times 
velocity, where force is calculated as body mass times the acceleration of gravity and velocity is 
calculated as the height of the stairs divided by the time to complete the stair climb.152  High test-
retest reliability in community dwelling older adults with mild-moderate mobility limitations has 
been found for this measure (R=0.99).152 This method requires little equipment, just a well-lit 
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stairwell and stopwatch.  However, since these are relatively new methods of measuring muscle 
power, the feasibility and safety in different populations of older adults must be evaluated and 
appropriate data management and analytic methods established. 
Table 1.4. Advantages of different muscle power methods 
1.6 CONTRIBUTING FACTORS TO DECLINING NEUROMUSCULAR FUNCTION 
WITH AGE 
Due to the potential effects of neuromuscular decline on mobility related outcomes, 
understanding established and novel risk factors for increased neuromuscular decline with age is 
crucial. A longitudinal cohort study using 22 years of follow up data from the Mini-Finland 
Health Examination Survey examined a number of potential lifestyle and disease-related risk 
factor for decline in hand grip strength.170  Both strenuous work-related physical activity in 
midlife and becoming sedentary were associated with longitudinal decline in grip strength. 
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Being overweight or obese and smoking were related to greater decline in grip strength as were 
incident chronic conditions such as coronary heart disease, other cardiovascular disease, diabetes 
mellitus, chronic bronchitis, and chronic back syndrome, and  persistent conditions including 
cardiovascular disease, hypertension, and asthma.  The greatest observed effect was weight loss 
that exceeded 10% of body weight.  A limitation of this is that they only assessed grip strength 
when lower extremity strength may be more important for mobility. Findings should be 
confirmed in more ethnically and culturally diverse populations.  Moreover, identifying risk 
factors for lower-extremity strength and power is crucial given their established relationships 
with function and disability.155,156,158 
1.6.1 Muscle mass and muscle quality 
Loss of muscle mass with age and its association with strength decline has been clearly 
demonstrated, although strength declines independent of muscle mass,71,72 indicating the 
presence of additional contributing factors.  Muscle contractile quality, which is also called 
muscle quality, specific torque, or specific force, is a measure of strength per unit of muscle 
mass71,72 or force per single fiber. As a measure of force per fiber, it can be adjusted by the cross-
sectional area of the fiber.171  Muscle quality, particularly strength per unit of mass, which also 
declines with age, may account for much of the component of strength decline that is not 
explained by loss of lean mass.71,172 Effects of nerve function on measures of muscle quality 
have yet to be explored.  
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1.6.2 Effects of muscle structural changes 
In addition to decreasing mass, a number of structural changes occur within the muscle with age 
and likely contribute decline in muscle quality and function.  Age-related changes in muscle 
fiber type composition41,42 (see section 1.2 on the pathophysiology on muscle aging) are thought 
to play a key role in declining muscle strength and power.  As mentioned previously, aging 
muscle is characterized by a grouping of type I (slow twitch) and type II (fast twitch) fibers and 
disproportionate reduction of type II. 41,42   Individually, type II fibers can generate four times the 
power output of type I fibers.43  Moreover, type II fiber area may be more strongly associated 
with strength than type I fiber area.41,173  However, limited evidence exists that changes in fiber 
type distribution in late-life directly contribute to declines in muscle function.  One study did 
find that while the percent of type II fibers measured in human muscle biopsy samples was not 
correlated with strength, a greater percent of type IIB fibers was correlated with greater speed of 
movement.41  The relationship between fiber type percentages and power were not studied. 
However, this finding suggests that type IIB fiber distribution could be related to power, since 
velocity is the component of power that distinguishes it from strength.  In addition, resistance 
training in older adults, resulting in increased strength (and likely power, although this was not 
assessed), may also lead to increases in the area and amount of type II fibers, while the area and 
amount of type I fibers remain unchanged.174,175  Although, whether fiber type distribution in a 
small biopsy sample adequately reflects overall distribution in vivo is unclear.  
Myosteatosis, defined as fat infiltration in skeletal muscle, increases with age72 and is 
associated with changes in muscle function in late-life.  Fat depots within skeletal muscle can be 
characterized as three types: 1) intermuscular adipose tissue; 2) intramyocellular fat; and 3) 
extramyocellular fat (for a review see Miljkovic and Zmuda, 201067).  Intermuscular adipose 
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tissue (IMAT) is located within the fascia surrounding muscle. Using computed tomography 
(CT) or magnetic resonance imaging (MRI), this fat depot can be seen as marbling between 
muscle tissue.  CT can also be used to quantify muscle density33 or muscle attenuation,133 for 
which low values reflect greater IMAT.  Using data from the Health ABC study, Goodpaster and 
colleagues computed skeletal muscle attenuation coefficients, where higher values indicated less 
fat content within the muscle.133 Higher attenuation coefficient was associated with greater 
muscle quality, or specific force production, independent of muscle mass.  Longitudinal analysis 
of data from the same study, showed that lower attenuation, reflecting greater fat infiltration, was 
associated with both decreased strength and increased risk of incident mobility limitations, 
assessed using self-reported difficulty walking a quarter or a mile and climbing 10 steps without 
resting.176 CT, however, cannot distinguish intramyocellular fat, which occurs within muscle 
fibers, or extramyocellular fat, which occurs as small quantities of lipid droplets surrounding the 
muscle fiber.  These muscle depots can be quantified using magnetic resonance spectroscopy 
(MRS) or by examining biopsied muscle tissue. Intramyocellular fat also increases with age.177  
Given its positive association with insulin resistance and diabetes, many early cross-sectional 
studies focused on the metabolic properties of intramyocellular fat.  However, this association is 
not present in endurance trained athletes who tend to have greater intramyocellular fat. This has 
been termed the “athlete’s paradox”,178 although later studies have found exercise-induced 
increases in intramyocellular fat in both inactive healthy and insulin-resistant older adults.179,180  
Moreover, these increases in intramyocellular fat were associated with improvements in insulin 
sensitivity in overweight and obese participants.180 Despite the demonstrated effects of exercise 
on intramyocellular fat, the relationship between intramyocellular fat and physical and muscle 
function has not been investigated. In addition, fat infiltration is known to occur in those with 
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severe clinical neuropathy.181 In a population-based study of European white older adults, low 
motor amplitude less than <4mV, suggesting axonal degeneration was associated with lower calf 
muscle density.33  Early work by Strotmeyer and colleagues shows that poor sensory and motor 
nerve function is associated with higher IMAT in older men.182 Future work should examine 
whether these structural changes could mediate the relationship between nerve and muscle 
function. 
1.6.3 Mitochondrial dysfunction 
Mitochondrial dysfunction, which is thought to be a consequence of damage to muscle 
mitochondrial DNA that accumulates with age,126 may result in decreased metabolic rate of 
protein synthesis, ATP synthesis, increased muscle cell apoptosis, and loss of muscle mass, as 
described in the mitochondrial theory of aging.183,184 However, whether this is primarily due to 
lower physical activity in older adults is somewhat controversial.  Some evidence suggests that 
age-related declines in mitochondrial function can be reversed through exercise training.185-187  
Others suggest that impairment in mitochondrial function with age is only partially attenuated 
with exercise.188  Additional research is needed to determine whether these improvements in 
mitochondrial function translate into improvements in muscle function. Research on the 
association between mitochondrial function and peripheral nerve function is lacking, although 
Lin and Beal hypothesize that mitochondrial dysfunction plays a major role in neurodegenerative 
disease through generation of reactive oxygen species and regulation of apoptosis.189 In addition, 
down regulation of mitochondrial function has been implicated in type II diabetes, a major risk 
factor for neuropathy, through genetic linkage and mouse model studies (for review see Wallace, 
2005).190
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1.6.4 Excitation contraction uncoupling 
Animal studies show evidence of excitation-contraction uncoupling with age. Excitation-
contraction coupling is the process whereby electrical signaling from the neuron (the action 
potential) is converted into a mechanical response (muscle contraction).  Age-related uncoupling 
is thought to result from a detaching (or uncoupling) of the ryanodine receptors, which are 
responsible for releasing the Ca2+ ion, from the voltage-sensing dihydropyridine receptor units. 
This results in a reduction in the release of the calcium ion and diminished contractile force.191  
Much of the research in this has been limited mice and rats;191-193 however, there has been some 
work confirming the presence of uncoupling in single in vitro human muscle fibers from a small 
sample of healthy older adults.194 To what extent this occurs in mobility-limited older adults is 
unknown and evidence is limited on the direct relationship between excitation contraction 
uncoupling and muscle function in humans (for review see Jimenez Moreno, et al., 2006195). 
1.6.5 Hormones 
Age-related changes in hormones also likely play a role in neuromuscular impairments in late 
life.  Declines Insulin-like growth factor-I (IGF-I) may contribute to sarcopenia and declines in 
nerve function.  IGF-I is important for growth, differentiation, and repair of both muscle196,197 
and nerve cells198,199 and for nerve cell apoptosis.  In animal models, overexpression of IGF-I can 
lead to increased reinnervation of skeletal muscle after injury,200 prevention of age-related loss of 
skeletal muscle mass201 and excitation-contraction uncoupling,202 and maintenance of muscle 
fiber-specific force.203  A recent study of older adult, showed that the IGF-I CA-repeat 
polymorphism does not influence changes in peak muscle power with strength training.204  
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Testosterone levels also decrease with age and have been shown to contribute to loss of muscle 
mass205  although evidence of its effects on muscle function is somewhat conflicting.205,206  
While some evidence suggests that testosterone administered to older adults with low levels may 
increase muscle mass, strength, and protein synthesis,207-211 findings are still inconclusive as to 
whether testosterone therapy improves muscle strength and function in community-dwelling 
elderly.212 
1.6.6 Inflammatory cytokines 
Aging is associated with an increase in pro-inflammatory cytokines that may be associated with 
catabolic effects on muscle; however, evidence is conflicting on whether these cytokines predict 
sarcopenia in older adults.  IL-6 has both pro- and anti-inflammatory effects in relation to 
skeletal muscle.  As a pro-inflammatory cytokine, it may mediate the catabolic effects of wasting 
diseases and sarcopenia in the elderly.  Yet, it has also been implicated in metabolic control 
pathways during exercise and some suggest that it may play an anti-inflammatory role as an 
inhibitor of the production of inflammatory mediator TNF-α.  In addition, IL-6 may interfere 
with growth hormone (GH) and insulin-like growth factor (IGF)-I, which are essential mediators 
of skeletal muscle growth.  Evidence from mice studies indicates that IL-6 may induce changes 
in growth factor-related signaling and catabolism and that downregulation of growth factor-
mediated intracellular signaling may act as a mechanism for IL-6 induced muscle atrophy.213   
Data from the Health ABC Study shows that high serum levels and soluble receptors of 
inflammation markers, such as IL-6 and TNF-α, are associated with a greater decline in muscle 
mass and strength over five years.214  Some of these associations were attenuated by adjustment 
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for change in weight, suggesting that that there may be a weight-associated pathway for 
inflammation in sarcopenia.  
1.6.7 Nutrition 
Various nutritional deficiencies, such as inadequate protein intake, vitamin D deficiency, and 
low vitamin B12 have been implicated in neuromuscular decline and particularly decline in lean 
mass with age (for reviews see Morley et al.,215 Forbes et al.216, and Robinson et al.217).  Not only 
do older adults tend to intake less than the recommended daily allowance (RDA) of dietary 
protein, but their muscles may also produce less protein due to metabolic changes that occur with 
age.218  The Health, Aging, and Body Composition Study found that older adults in the highest 
quintile of protein intake had 40% less decline in appendicular lean mass when compared to 
those in the lowest quintile.219  While it is generally accepted that adequate levels of protein are 
needed to maintain muscle mass in old age,215-217,220 evidence that increasing protein intake alone 
can prevent or even reduce the risk of sarcopenia is limited. Trials comparing the combination of 
strength training and protein supplementation to strength training alone have produced 
conflicting finding of its efficacy for promoting gains in muscle mass.221-224  The effect of protein 
intake on muscle function in the elderly is largely understudied.  Existing evidence suggests that 
protein intake may only be associated with change in muscle strength in older adults with high 
levels of inflammatory markers.225 The optimal amount of protein intake in late life is also 
unknown, however, it has been suggested that older adults may require more than the current 
RDA of 0.8 g/kg/day.215  Studies on the supplementation of amino acids necessary for protein 
synthesis, such as Leucine, have also yielded conflicting findings.226-228  Clearly, more research 
is needed in this area.  
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Vitamin D deficiency is common in the elderly229-232 and has been associated with low 
muscle strength233,234 and impaired nerve function.235-238  Very low levels of vitamin D can lead 
to osteomalacia, which is a clinical syndrome involving under-mineralization of bone and is 
associated with muscle weakness.239  A recent meta-analysis demonstrated that daily vitamin D 
supplementation between 800 and 1,000 IU had a beneficial effect on strength and balance in 
older adults.240  However, it is unknown to what extent this improvement in function is due to 
changes in nerve function, lean mass, or other mechanisms. In addition, the Institute of 
Medicine’s review of randomized controlled trials and observational studies indicates lack of 
sufficiently strong evidence supporting the effect of vitamin D supplementation on physical 
function and falls. This was due, in part to lack of high quality observational evidence and varied 
significance in randomized controlled trials.239 
Deficient levels of the vitamin B12 also have negative neuromuscular consequences.  
Deficiency can cause nerve demyelination and has been associated with neuropathy,241-243 lower 
extremity weakness,244 decline in physical performance,245 loss of position sense,246 bone loss, 
and fracture.247,248  Moreover, subclinically low levels of B12 have been related to low sensory 
(monofilament detection) and motor (nerve conduction velocity) peripheral nerve function in 
older adults.249,250 There have been no clinical trials in older adult assessing whether vitamin B12 
supplementation influenced muscle function or physical performance. 
1.6.8 Disease related risk factors 
One limitation of many studies of strength and power decline with age is that they do not address 
any disease related risk factors. Diabetes mellitus is a major risk factor for clinical neuropathy 
and has been implicated as an important risk factor for decline in neuromuscular function.  Older 
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adults with type 2 diabetes have worse muscle strength (4% lower) and quality (7-8% lower).251 
They also show greater declines in strength and quality (33% greater declines for both).252  While 
there has been little work on the effects of diabetes on muscle power, a small study found that 
older adults with concurrent diabetes, peripheral neuropathy, and obesity had lower muscle 
strength power.253 In this study, the independent effects of diabetes could not be assessed. In 
early work using data from the Health ABC study, we have shown that adjustment for diabetes 
attenuated associations between power and self-reported physical function, explaining a portion 
of the association.254 Associated neuropathy is likely an important mechanism in the relationship 
between diabetes and poor muscle function since the severity of neuropathy and the fiber density 
and amplitude of motor units was associated with strength.  However, in the Health ABC study 
(ages 70-79 at baseline), Strotmeyer and colleagues found that diabetes predicted lower 
extremity function independent of peripheral nerve function.20,21 Increased inflammatory 
cytokines , such as TNF-α and IL-6 may also play an important role, since they are associated 
with impaired muscle mass, strength and physical performance and partially attenuate the 
relationship between diabetes and loss of strength and muscle quality.  Insulin resistance also 
leads to impaired mitochondrial function which likely contributes to neuromuscular health. 
Those with diabetes also tend to experience a greater amount of intermuscular adipose tissue, 
termed myosteatosis,71,133  which has been linked to decreased strength and a higher incidence of 
mobility limitations.133,176 
Peripheral Arterial Disease (PAD) is also an important risk factor for neuromuscular 
decline.255,256 PAD is defined often subclinically in older adults as ankle brachial index (ABI) < 
0.9. PAD is associated with poor sensorimotor nerve conduction, lower calf muscle area and 
density and a higher percentage of calf muscle fat, which may lead to worse physical 
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performance.255,256  Muscle power may attenuate the relationship between PAD and poor 
physical performance in older adults.255,257  Both cross-sectional muscle area and nerve 
conduction velocity (NCV) did not attenuate this relationship; however, NCV was only 
measured in the right leg, even if the left leg had lower ABI. Muscle strength has not been 
examined as a mediator.  The role of PAD in neuromuscular decline is likely due to ischemia 
(decline in blood flow) to distal nerve and muscle tissue resulting in denervation, muscle 
atrophy, and reduced perception, diminished oxygen for muscle fibers to use.38  Occlusion of 
vessels leading to decreased blood flow and insufficient oxygen can result in an impaired 
capacity to replenish ATP and creatine phosphate.  This can inhibit cross-bridge interaction 
between actin and myosin, leading to fatigue.258-260  Ischemia prevents adequate oxygen delivery 
which can delay ATP and creatine phosphate resynthesis.38 This can contribute to fatigue during 
muscle contractions,259,260 potentially leading to decreased muscle strength and power.261  An 
additional mechanism between PAD and impaired physical function that has been proposed is 
that those with PAD may reduce their walking speed to avoid ischemic leg symptoms.257  Over 
time, this could result in detrimental changes to muscle, further contributing to worse lower 
extremity function.257  Alternatively, asymptomatic participants with PAD may experience 
primary insult to lower extremity nerves (maybe related to ischemia) potentially inducing 
denervation atrophy of muscles and reduced perception of lower extremity ischemic 
symptoms.257 
1.6.9 Central nervous system 
With older age, a reduced evoked potential of neurons within the motor cortex of the brain and 
the spinal cord have been observed using transcranial magnetic stimuli.262  These corticospinal 
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neurons and their increased activation (termed central activation) are linked to increased force of 
contraction, and therefore their decreased activation is believed to be linked to a decrease in 
force.  Imaging has also demonstrated age-related atrophy and changes in and around the motor 
cortex,263-266 however, if and how these changes are directly related to loss of muscle function is 
not known.  A higher intensity stimulus is required to achieve maximal motor evoked potentials 
with older age.267  This is suggestive of the role of the central nervous system in submaximal 
activation during maximal voluntary contractions (MVC) with age, necessary for strength and 
power output.19  However, some limitations to the methodology available exist for assessing the 
involvement of the central nervous system in MVC with age.  Involvement of the cortex, spinal 
cord, and neuromuscular junction is typically measured through voluntary activation of muscle 
fibers268 using the interpolated twitch technique.  The interpolated twitch technique entails 
supramaximally stimulating motor axons of contracting muscles during MVC.  This additional 
stimuli is thought to recruit muscle fibers that have not been activated through voluntary effort, 
allowing for their quantification.19  A notable limitation of this technique that has been suggested 
is that it may overestimate voluntary activation when using single or paired stimulation and has 
reduced sensitivity for detecting activation failure above 90% of MVC.188,189  Single or paired 
stimulation is more easily tolerated than repetitive “train” stimulation, although it does not allow 
for summation of forces, and may therefore only represent a small fraction of the torque 
production during MVC.  Moreover, findings on whether central voluntary activation decreases 
with age have been conflicting and dependent on the muscle studied19,269 and on the age of the 
participants.270  For instance, a decrease in central activation has been observed for the knee 
extensors and elbow flexors, particularly in older adults greater than 70 years of age, but this 
39 
decrease in activation has not been observed in the dorsiflexors.10,19  Moreover, longitudinal data 
to look at age-related changes is severely lacking.  
1.7 STRENGTH AND POWER TRAINING 
Until recently, exercise interventions for older adults designed to increase muscle function 
mostly focused on resistance training with only modest gains in muscle power.11,271  More 
recently, some focus has shifted to improving muscle power in older adults with specificity 
training. Many of these interventions have used some form of high velocity resistance training, in 
which the concentric phase is performed as quickly as possible, aimed at increasing muscle 
power and physical function. Table 1.5 summarizes findings from these studies.  A number of 
these studies tested comparative effectiveness with more traditional strength training.  Compared 
to traditional strength training, high velocity power training lead to greater improvements in 
power, but similar improvements in strength.  Both strength and power training generally lead to 
improvements in physical function, such as the short physical performance battery 
(SPPB),161,272,273 stair climb time,161,274 chair rise time,274,275 gait speed,161,274,276 the timed up and 
go,275 the Continuous Scale Physical Functional Performance,277 counter movement jump 
height,160  and self-reported function.272   In some cases power training lead to greater 
improvements in physical function than strength training, but in other cases, improvements in 
physical function were not significantly different between training groups. In all cases, strength 
and power training was well tolerated in older adults, even among those with self-reported 
disability.278  Explosive training with heavy loads (80% of 1RM) have been found to be more 
effective than lighter loads (50% and 20% of 1RM) at improving muscle strength, whereas both 
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heavy and light loads may be equally effective at improving power.279  While explosive training 
with heavy loads may be safe in healthy older adults,160 evidence is lacking in those with 
mobility limitations and in individuals susceptible to pain. These studies have been limited by 
small sample sizes and short-training durations (3-24 weeks). More research is needed diverse 
populations of older adults with varying physical abilities.  
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Table 1.5. Strength vs. power training 
Study Population Training 
Group 
↑ Power  ↑ Strength ↑ Physical 
function 
Fielding, 
2002278 
• N=30
• Mean age 73 ± 1
• Women with self-reported
disability
PT ↑↑ ↑ -- 
ST ↑ ↑ -- 
Miszko, 2003277 • N=39 
• Mean age  72.5 ± 6.3
• Leg extensor power <140W
(women), 210W (men)
PT ↑ ↑ ↑ 
ST ↑ ↑ 0 
Henwood, 
2008274 
• N=67
• Mean ages 70.7 ± 5.5, 70.2
± 5.0, 69.3 ± 4.1, 69.1 ± 3.6
• Community dwelling older
adults
PT -- ↑ ↑ 
ST -- ↑ 0 
Bottaro, 2007275 • N=24 
• Mean age 66.4 ± 5
• Healthy, inactive men
PT ↑↑ ↑ ↑↑ 
ST ↑ ↑ 0 
Caserotti, 
2008160 
• N=56
• Mean ages 62.7 ± 2.2 and
81.8 ± 2.7
• Community dwelling
women
PT ↑ ↑ ↑ 
ST -- -- -- 
Reid, 2008280 • N=57
• Mean age 74.2 ± 1.4
• Mobility limited (mean
SPPB 7.7±1.4)
PT ↑↑ ↑ -- 
ST ↑ ↑ -- 
Marsh, 2009281 • N=45 
• Mean age 75.8 ± 5.7
• ADL difficulty
PT ↑↑ ↑ -- 
ST ↑ -- 
Bean, 2009272 • N=138
• Mean age 75 ± 6.8
• Mobility limited (mean
SPPB 7.7±1.4)
PT ↑↑ ↑ ↑ 
ST ↑ ↑ ↑ 
Holsgaard-
Larsen, 2011282 
• N=19
• Mean age 69.7 ± 3.4
• Women
PT -- -- ↑ 
ST -- -- -- 
Drey, 2011273 • N=69
• Mean ages 76 (70-82), 78
(73-84), 77 (72-80)
• Prefrail (Freed definition)
PT 0 0 ↑ 
ST 0 0 ↑ 
↑ = Increased with training 
↑↑ = Increased significantly more than comparative training group 
0 = No effect 
-- = Not assessed 
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1.8 LIMITATIONS IN THE LITERATURE 
A number of important limitations in the literature need to be addressed.  First, many individuals 
with neuropathy may go undiagnosed22 and remain asymptomatic,23 particularly in those without 
diabetes, therefore subclinical measures of poor nerve function should be included in studies of 
older adults. The prevalence and incidence of poor nerve function in subgroups of older 
populations is unknown and should be assessed, particularly given the health disparities of 
disease related risk factors for neuropathy. The effects of diabetes on muscle power should be 
studied and mechanisms for its relationship with strength should continue to be uncovered. In 
addition, while diabetes remains an important risk factor for neuropathy, neuropathy remains 
quite prevalent in older adults without diabetes23 and diabetes does not fully account for the 
relationship between neuropathy and poor mobility outcomes,20,21 therefore other known and 
novel risk factors should continue to be explored, particularly using longitudinal data. There is 
limited longitudinal data on nerve function in older adults. Specifically, data from longitudinal 
cohort studies are needed to confirm age-related physiologic and functional declines and to 
assess relationships between nerve function, muscle structure and function, and physical 
function. The relationship between muscle power and clinical measures of nerve function, such 
as those from nerve conduction studies and monofilament testing should be investigated. Direct 
comparison of the relationship of strength vs. power with nerve function and physical function 
are lacking. Since there are a number of methods currently used to measure muscle function, and 
particularly muscle power, optimal methods of measurement in older adults need to be evaluated 
for feasibility and validity in relation to key outcomes and predictors, such as physical function 
outcomes, nerve function, and muscle characteristics like mass, quality, fiber type composition 
and mitochondrial function. More research is needed on interventions for neuromuscular decline. 
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This includes research on training interventions with longer durations, larger sample sizes, and 
more functionally diverse populations, investigating the specificity, intensity, and volume of 
training needed to prevent or slow declines in neuromuscular and physical function.  
1.9 OBJECTIVES AND SPECIFIC AIMS 
This dissertation will address limitations in the literature by using prospective data to investigate 
the relationships between peripheral nerve function and muscle power, strength, and mobility 
limitation in older adults. Our objectives include assessing whether cross-sectional and change in 
sensory and motor peripheral nerve function are associated with lower extremity muscle power 
in community dwelling older men from the Osteoporotic Fractures in Men Study (MrOS). We 
will investigate the relationship between motor and sensory peripheral nerve function and 
longitudinal quadriceps strength in a large cohort of community dwelling older men and women 
from the Health Aging and Body Composition (Health ABC) Study. Finally, using data from the 
Health ABC Study we will assess the relationship between sensory and motor nerve function 
over seven years and incident mobility limitation. The specific aims and hypothesis of this 
dissertation are listed below. With these objectives, this dissertation will help characterize the 
role of neuromuscular impairment in the disablement pathway. 
Aim 1. To assess the cross-sectional and longitudinal relationship between sensory and 
motor nerve function and lower extremity muscle power. 
Hypothesis 1a. Poorer nerve function will be associated with diminished lower extremity 
muscle power. 
Hypothesis 1b. Poorer nerve function will independently predict decline in muscle power. 
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Hypothesis 1c. Decline in nerve function will predict concurrent decline in muscle power. 
Aim 2. To assess the relationship between baseline and longitudinal change in sensory 
and motor nerve function to longitudinal change in lower extremity quadriceps strength. 
Hypothesis 2a. Poorer baseline nerve function will independently predict decline in 
quadriceps strength. 
Hypothesis 2b. Seven-year decline in nerve function will be associated with concurrent 
decline in quadriceps strength. 
Aim 3. To investigate whether poor baseline and longitudinal change in sensory and 
motor peripheral nerve function predict incident mobility limitation. 
Hypothesis 3a. Worse baseline sensory and motor nerve function will be associated 
shorter time to incident disability. 
Hypothesis 3b. Greater decline in nerve function will be associated with shorter time to 
incident disability. 
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2.1 ABSTRACT 
Objective: To assess whether cross-sectional and change in sensorimotor peripheral nerve 
function are associated with lower extremity muscle power in a cohort of community dwelling 
older men. 
Design: Longitudinal cohort study. 
Setting: One U.S. clinical site. 
Participants: Three hundred seventy-two participants from the Osteoporotic Fractures in Men 
(MrOS) Study (age = 77.2 ± 5.1 years, 99.5% white, BMI= 27.9 ± 3.7 kg/m2, power = 1.88 ± 0.6 
watts/kg). 
Measurements:  Measurements were collected during a nerve function ancillary study performed 
4.6 ± 0.4 years after baseline and a follow up visit that occurred 2.3 ± 0.3 years after the first visit. Muscle 
power was measured in each leg using the Nottingham Power Rig. Motor nerve conduction amplitude, 
distal motor latency, and mean f-wave latency were measured at the deep peroneal nerve.  Sensory nerve 
function was assessed using 10-g and 1.4-g monofilaments and sensory nerve conduction amplitude and 
distal sensory latency were measured at the sural nerve.  Symptoms at the leg and feet (numbness or 
tingling; sudden stabbing, burning, pain or aches; and open or persistent sores) were assessed by self-
report. Adjusted models include age, height, total body lean and fat mass or calf muscle volume and 
muscle density in place of lean and fat mass, Physical Activity Score for the Elderly (PASE), diabetes, 
ankle-brachial index, hypertension, hip pain, stroke, congestive heart failure, and Teng Modified Mini-
Mental State Exam (3MSE) score. 
Results:  After adjusting for age, height, total body lean and total body fat mass, one standard 
deviation lower motor and sensory amplitude (β = -0.07, β = -0.09, respectively;  both p < 0.05) and 1.4-g 
and 10-g monofilament insensitivity (β = -0.11 and β = -0.17, respectively; both p < 0.05) were associated 
with lower muscle power/kg in separate linear regression models.  Compared to the effect of age on 
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muscle power (β per year = -0.05 , p < 0.0001), this was equivalent to aging 1.4 years for motor 
amplitude, 1.8 years for sensory amplitude, 2.2 years for 1.4-g monofilament detection, and 3.4 years for 
10-g detection. Baseline 1.4-g monofilament detection predicted greater decline in power/kg. Short-term 
change in nerve function was not associated with concurrent short-term change in power/kg. 
Conclusion:  Motor and sensory nerve conduction amplitude and monofilament sensitivity were 
associated with lower power/kg. Sensory and motor nerve function may play an important role in 
impaired muscle function in older men.  Simple screening for monofilament detection may potentially 
identify muscle function decline in late-life, which has implications for disability in older adults. 
2.2 BACKGROUND 
Lower extremity muscle power is an important determinant of late-life physical function 
mobility.153,158 While muscle strength is a measure of the ability to produce force, muscle power 
is a measure of both force and contractile speed.  Loss of muscle power in older adults has been 
linked to risk of falls283 and loss of mobility as measured by physical performance tests such as 
walking, chair stands, or stair climbing70,140-142,149,151,152,166 and self-reported functional 
status.143,153 Studies suggest that, compared to strength, muscle power declines more steeply with 
age69,70 and may be more strongly associated with certain measures of mobility.140,141,142 ,143 
Moreover, training programs designed to improve muscle power and velocity of movement may 
be more effective at improving physical performance than those that solely incorporate basic 
resistance training.160,278,284  
Although the exact etiology remains somewhat unclear, poor muscle power in late-life 
and its unique relationship with mobility may be, at least in part, due to impairments in 
peripheral nerve (PN) function.2,41,74,144-146  Force and velocity production (the two components 
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of muscle power) are likely dependent on the number and firing rate of motor units, consisting of 
neurons and their associated muscle fibers.84  In addition, afferent input from impaired sensory 
nerves may play an important role in muscle and physical function through loss of 
proprioception.12,13  Like muscle power, PN function has been found to decline with age. 
22,23,26,285,286  The 1999-2000 National Health and Nutrition Examination Survey (NHANES) 
showed that 35% of adults aged 80 years and older had impaired nerve function measured using 
simple screening for reduced sensation at the foot.23  Decreased PN function in old age has 
similarly been linked with physical function limitations and impairments26,27 and increased risk 
of falls.28-30 Additionally, poor sensory and motor PN function has been related to reduced lower 
extremity quadriceps strength in the Health Aging and Body Composition Study.21   
Despite the importance of muscle power and nerve function for mobility-related 
outcomes and the assumed etiologic relationship between them, the relationship of power with 
motor and sensory PN measures commonly used in clinical evaluations and neurologic studies 
has not been quantified. In a longitudinal cohort study of older men, we evaluated the whether 
sensory and motor PN function is related to lower extremity muscle power cross-sectionally and 
longitudinally with the hypothesis that worse and declining nerve function is associated with 
poor and declining muscle power. 
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2.3 METHODS 
2.3.1 Study population 
We used data from a nerve function ancillary study in which 372 participants had nerve function 
and power measured during the first visit and 242 participants had these repeated during a 
second visit. The ancillary study was performed at the Monongahela Valley site and occurred 4.6 
± 0.4 years after baseline visits, which occurred between 2000 and 2002. The second visit to the 
ancillary study occurred 2.3 ± 0.3 years after the first. This ancillary study was part of the 
Osteoporotic Fractures in men study (MrOS), which is a cohort of community dwelling, 
ambulatory men (N = 5994) aged 65 years and older enrolled between March 2000 and April 
2002 at six U.S. clinic sites (Birmingham, AL; Minneapolis, MN; Palo Alto, CA; Monongahela 
Valley near Pittsburgh, PA; Portland, OR; and San Diego, CA; n=1005 in Pittsburgh at baseline).  
Eligibility for the main study included ability to walk without assistance of another person or an 
aide, ability to provide self-reported data, ability to understand and sign an informed consent, 
absence of bilateral hip replacements, absence of a medical condition that would result in 
imminent death, and residence near a clinic site for the duration of the study period. The primary 
recruitment strategy was mailing invitations to men living in the surrounding communities of the 
clinic sites. Supplementary strategies included community and senior newspaper advertisements 
and presentations to community groups. The study protocol was approved the University of 
Pittsburgh institutional review board and written informed consent was obtained from all 
participants prior to testing. Out of the 662 men with nerve function measured during the first 
visit of the ancillary study, 372 had muscle power and were included in cross-sectional the 
analyses.  Reasons for missing muscle power included a temporary equipment failure (n = 205), 
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refusal (n = 11), and unable due to physical limitation (n = 74). Participants with missing cross-
sectional muscle power data did not differ by age, but had slightly higher BMI (28.6 vs. 27.9 
kg/m2, p = 0.03) and a higher prevalence of diabetes (27.9% vs. 17.0%, p < 0.001). Out of the 
participants included in the cross-sectional analysis, 297 returned for a second follow-up visit of 
the nerve function ancillary. The change analysis included data from 242 participants with 
complete nerve function and muscle power data from the first and second visits of the ancillary 
study. During the second visit, 1 participant refused muscle power testing and 53 participants 
were unable due to physical limitations. Participants with missing data for the change analysis 
were older (78.8 vs. 76.3 years, p < 0.0001), but had similar BMI and rates of diabetes.  
2.3.2 Lower extremity muscle power 
Muscle power was measured using an unloaded single leg extension (Nottingham Leg Extensor 
Power rig, Nottingham, U.K.).165  Participants were seated with their arms crossed over their 
chest and instructed to push down on a pedal with one foot as hard and as fast as possible 
through full range of motion.  Pushing the pedal transmits energy through a lever and chain to 
accelerate a flywheel.  The velocity of the flywheel is measured with an optoswitch and used to 
calculate the power output.  Peak power was measured in watts as the maximum power output 
from five trials.  Both sides were tested unless the participant had a hip replacement on one side. 
The ratio of power to body weight in kg was chosen as the outcome of interest since it may better 
reflect ability to move one’s body weight during normal daily functioning.  
To correspond with sensory nerve conduction measures, muscle power data on the non-
dominant side was used in the analysis unless prohibited by missing data because of inability due 
to physical limitation.  In the case that no sensory nerve conduction data were available, muscle 
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power data was matched to the side in which motor nerve conduction and/or monofilament 
testing were performed.  The number of participants with discordant sides analyzed due to 
missing data was minimal (n = 5 for motor nerve conduction and n = 1 for monofilament 
testing).  
2.3.3 Peripheral nerve measures 
Nerve conduction was measured bilaterally on the deep peroneal motor and sural sensory nerves 
using an automated nerve conduction study device (NC‐stat®, NeuroMetrix, Inc., Waltham, 
MA).287  This device has been previously validated in healthy older adults with gold standard 
nerve conduction studies (correlation coefficient > 95%).288  If participants’ feet were less than 
30° C, they were warmed to at least 30° C prior to testing. The parameters recorded from the 
peroneal motor nerve included the compound muscle action potential (CMAP) motor amplitude 
in millivolts (mV), measured from baseline to the negative peak of the CMAP waveform, the 
distal motor latency (DML) in milliseconds (ms), the time from the stimulus to the onset of 
motor activity, and mean F-wave latency (FWL) in ms, the mean value of the time from stimulus 
to the onset of F-wave activity.  Sural sensory nerve measures included the sural nerve action 
potential (SNAP) sensory amplitude in microvolts (µV), the difference between negative and 
positive peak of the SNAP waveform and the distal sensory latency (DSL) in ms, the time from 
the stimulus to the negative peak of the SNAP.  Light (1.4-g) and standard (10-g) monofilament 
sensitivity were defined as ability to detect three out of four touches at the dorsum of the both 
great toes. Insensitivity was defined as inability to detect three touches. The standard 
monofilament was performed only if the participant could not feel the light monofilament. 
Sensory nerve conduction was performed on the non-dominant side.  Motor nerve conduction 
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and monofilament testing were performed on both sides unless technical difficulty occurred. 
Participants were asked whether they experienced neuropathic symptoms within the past 12 
months.  These included having:  (1) numbness or tingling, (2) sudden stabbing, burning, pain or 
aches, and (3) an open or persistent sore, or gangrene on either feet or leg.  A count of symptoms 
was calculated from 0-3. All measures were repeated at the follow-up visit. 
2.3.4 Additional covariates 
All models were adjusted for age and height, measured using a stadiometer. Weight was 
measured with a calibrated balance beam scale but was not included as a covariate since 
power/kg of body weight was the outcome. Since one potential characteristic of overt neuropathy 
is atrophy of muscle fibers,34 lean mass was included as a potential mediator of the relationship 
between nerve function and power.  Fat mass, was included due to its important metabolic and 
functional consequences.289,290 Lean and fat mass were measured using dual-energy X-ray 
absorptiometry (DXA; Hologic 4500A, Hologic, Inc., Bedford, MA).  To ensure reproducibility 
of DXA measurements, standardized measurement and quality-control procedures were used and 
operators were certified. More localized measures of calf muscle density, which has been 
positively associated peroneal motor amplitude,33 and muscle volume, were added in place of 
lean and fat mass as potential mediators.  Muscle density in mg/cm3, a measure of intermuscular 
fat, and muscle volume (mm2) were measured at 66% of the calf length using peripheral 
quantitative computed tomography (pQCT - Stratec XCT-2000 scanner, Pforzheim, Germany) as 
previously described.291  Each of the following covariates was added to the model since they 
were significantly related to muscle power or one of the nerve function predictors at an alpha 
level of 0.1. Diabetes was defined by self-report, use of hypoglycemic medications or having a 
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baseline fasting glucose ≥ 126 mg/dl.292  Other chronic health conditions included self-reported 
hypertension, congestive heart failure, myocardial infarction, stroke, osteoarthritis, hip pain and 
Parkinson’s disease.  Participants self-reported if a doctor or other healthcare provider had ever 
told them that they had the condition.  Ankle-brachial index less than 0.9 was used to define 
peripheral vascular disease and greater than 1.3 was used to define arterial stiffening.  Cognitive 
function was assessed using the Teng Modified Mini-Mental State Exam (3MSE).293 Lifestyle 
factors included smoking status (both past and current), alcohol use (>1 drink/week) and physical 
activity measured using the Physical Activity Scale for the Elderly (PASE). 294 Variance inflation 
factors (VIF) were calculated to assess collinearity). No VIF exceeded 3.  
2.3.5 Statistical analysis 
Jonckheere-Terpstra tests and Analysis of Variance (ANOVA) were used to test for trends in 
participant characteristics across weight-adjusted muscle power tertiles.  Pairwise comparisons 
were made between muscle power tertiles using t-tests and chi-squared statistics.  Multivariable 
linear regression was used to compare: 1) each measure of baseline nerve function to baseline 
muscle power per kg of body weight; 2) each measure of baseline nerve function to change in 
muscle power/kg; 3) each measure of change in nerve function to change in muscle power/kg. 
Significant associations in the change analyses were then compared across tertiles and groups of 
baseline and nerve function change using least squared means adjusted for age, height, lean and 
fat mass for ease of interpretation.  Separate models for each measure of nerve function were 
built progressively in order starting with the measure of nerve function. Age and height were 
added to the first set of minimally adjusted models. Total body lean and fat mass were added to 
the second set of models. For the third set of models, lean and fat mass were replaced with more 
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localized measures of calf muscle density. And finally, models were adjusted for lifestyle factors, 
chronic health conditions and cognition to assess independent associations.   
2.4 RESULTS 
Participant characteristics were compared across muscle power tertiles (Table 2.1). Those in the 
lowest power tertile were older, shorter in height, and had a higher BMI, greater fat mass, lower 
lean mass, and were more likely to have a history of hypertension and myocardial infarction. 
Men in the lowest tertile also had lower motor and sensory amplitude and were less likely to 
have 1.4-g and 10-g monofilament sensitivity and more likely to report numbness symptoms in 
the leg or feet (Table 2.2).   
One standard deviation lower motor and sensory amplitude and standard touch 
monofilament insensitivity were associated with lower power/kg when adjusted for age and 
height (Table 2.3).  The associations between power and motor and sensory amplitude remained 
significant upon further adjustment for lean and fat mass, and confounders including lifestyle 
factors and chronic conditions (results not shown).  When we adjusted for calf muscle density 
and volume (results not shown) rather than lean and fat mass, the association between 
monofilament insensitivity and power was attenuated to nonsignificant by muscle density. 
Muscle density was positively associated with muscle power (β = 0.03, p < 0.001). The 
association of monofilament sensitivity with power was also attenuated to nonsignificant by low 
ankle arm index, which was borderline associated with muscle power (β = -0.11, p < 0.07).  
We then compared the effect sizes for significant nerve function variables from the 2nd 
Models to the effect size of age on muscle power in standard deviations of power/kg (Figure 
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2.1). One standard deviation lower motor and sensory amplitude had the effect of aging 1.4 and 
1.8 years, respectively and inability to detect 1.4-g and 10-g monofilament had the effect sizes of 
aging 2.2 and 3.4 years, respectively. Table 2.3 shows that inability to detect 1.4-g monofilament 
at baseline predicted a greater decline in muscle power/kg (least squared means = -0.08 vs. 0.07 
watts/kg, p = 0.02) when adjusted for age and height. Results were consistent when adjusted for 
lean and fat mass or muscle density and volume and additional covariates. Change in nerve 
function was not associated with a change in power. 
2.5 CONCLUSIONS 
Although muscle power is known to be dependent on both the nervous and musculoskeletal 
systems, previous research has not evaluated PN function measures commonly used in clinical 
practice and neurologic studies. Studies have indicated that muscle power declines at an even 
faster rate with age than strength,69,70 and our findings show that the potential effects of 
peripheral nerve function are 1.5 to 3.5 times the effect of age alone.  This finding has 
particularly important consequences, given that neuropathy is a preventable risk factor. 
Establishing the relationship between muscle power and clinically relevant measures of nerve 
function in late-life is crucial since older adults experience the highest burden of neuropathy and 
diminished muscle function and both likely play key roles in the disablement pathway.23,71 Our 
findings show that poor sensory and motor peripheral nerve function are independently 
associated with and may be important risk factors for poor muscle power in old age. Risk factors 
for poor muscle power are somewhat understudied in epidemiologic studies of older adults, yet 
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poor muscle power has important consequences in late-life such as impaired mobility,70,140-
143,149,151,152,166 disability,148,153 and increased risk of falls.283  
 We found that lower amplitude, but not latency, was associated with poor muscle power. 
Consistent with  our study findings, Strotmeyer and colleagues reported that peroneal motor 
nerve amplitude, but not conduction velocity, was related to lower extremity muscle strength.21 
Latency is the travel time of the response and is measured from the moment of stimulation to the 
appearance of the action potential.  Nerve conduction velocity is typically calculated by dividing 
the distance between two stimulation sites by the difference between latencies.65 Diminished 
amplitude may indicate axonal degeneration and motor nerve death, whereas latency or 
conduction velocity may be a measure of demyelination of the protective sheath surrounding the 
nerve.63  Amplitude may decline in some individuals, while velocity, driven by the motor units 
that remain intact, remains normal.33,76  In participants in the lowest muscle power tertile, we 
observed lower amplitude but no difference in latency, compared to those in higher muscle 
power tertiles (Table 2.2).  However, given that power is a measure of contractile velocity in 
addition to force, it is reasonable to hypothesize that the travel time, particularly for the motor 
nerve response, may be related to power. We, however, were not able to assess whether 
participants had low power due to low force or low velocity, since the power rig does not 
measure these two components separately. 
Sensory nerve function measured by monofilament detection and average vibration 
perception threshold was associated with muscle strength in the previous study as well.21  We 
found that sensory amplitude was also related to muscle power.  While motor nerves directly 
innervate muscle, it is less clear how the sensory nerves are involved.  Blocking afferent input in 
healthy individuals has led to impaired maximal voluntary contractions,13 which may occur 
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through loss of proprioceptive feedback.12  Furthermore, sensory neuropathy has been associated 
with significant loss of ankle movement perception.295,296  While an effort was made to collect 
multiple trials until a plateau in peak power was reached, it is possible that impaired sensory 
nerve function may have dampened participants’ ability to achieve proper foot placement and 
push at a maximum effort.  The fixed load single leg extension requires participants to push with 
their heel while maintaining contact between the pedal and the entire dorsum of the foot. 
Multiple trials may be needed for the participant to familiarize themselves with the movement 
and in some cases up to 9 trials may be need to produce a maximum effort.165  Assessing the 
relationship between nerve function and alternative methods of measuring muscle power may be 
an important future direction.  An additional explanation could be that large fiber neuropathies, 
which are the most common type of neuropathies in older adults,297 may affect both sensory and 
motor nerves, with most deficits first presenting as sensory loss. This can progress to reduced 
position sense, muscle weakness and wasting, and depressed tendon reflexes.297 Numbness and 
tingling were the most commonly reported neuropathic symptoms in this study with 30% of the 
total study population reporting them, supporting this hypothesis. There was also a significant 
trend across muscle power tertiles, with those in the lowest tertile being most likely to report 
numbness symptoms.  
Muscle density and low ankle arm index attenuated the relationship between 
monofilament sensitivity and muscle power to nonsignificant.  Interestingly, diminished nerve 
function in older adults has been previously associated with lower muscle density, a measure of 
intermuscular fat, but not with cross-sectional muscle area,33 which could suggest that age-
related changes in nerve function lead to changes in muscle tissue structure over macroscopic 
changes in muscle mass. Moreover, peripheral vascular disease measured using ankle arm index 
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has been associated with reduced leg muscle power and lower motor nerve conduction velocity, 
although the previous study did not examine sensory monofilament detection.255 
A major strength of this study is the inclusion of both motor and sensory PN function 
measures. We also used reproducible sensitive and specific measure of nerve conduction for both 
motor and sensory nerves.287,298 Our measure of muscle power has been previously validated and 
is commonly used.165 Models were adjusted for a number of potential confounders, including 
body composition measures, lifestyle factors, and comorbidities. And finally, we were able to 
examine longitudinal relationships between nerve function and muscle power change, although 
some of our null finding are likely attributable to the short time period (2.3 years) between 
measures. 
One limitation of this study is that our results may not apply to other populations such as 
non-whites, women, the “young-old” and institutionalized individuals. Future studies should 
assess the relationship between muscle power and clinical measures of motor and sensory nerve 
function in a larger more diverse population with a broader range of function.   
We showed that sensory and motor nerve function are independently associated with 
muscle power, which is associated with poor outcomes in older adults such as falls,283 impaired 
mobility,70,140-143,149,151,152,166 and disability.148,153 Future work should investigate whether there is 
a direct relationship between poor nerve function and these poor health outcomes. Since 
monofilament insensitivity was predictive of greater muscle power decline, future studies should 
also test whether simple screening for monofilament detection may identify early impairments 
and predict declines in muscle power. Detecting poor or declining muscle power early on could 
lead to more effective disability prevention and treatment efforts, such as training programs 
targeted at increasing muscle power. 160,278,284 Importantly, understanding risk factors in the 
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disablement pathway such as poor nerve function and impaired muscle power can help identify 
multiple points of intervention. Future studies should characterize the effects of known and novel 
risk factors of poor nerve function on muscle power. 
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Table 2.1. Characteristics of study population by muscle power (watts/kg) tertiles 
 Lowest tertile 
≤1.60 watts/kg 
(N=122) 
Middle tertile 
>1.60 and ≤2.06 
watts/kg 
(N=129) 
Highest tertile 
>2.06 watts/kg 
(N=121) 
p-value Total 
(N=372) 
Muscle power (watts/kg),  
mean (SD) 
1.27 (0.2)a,b 1.84 (0.1)c 2.52 (0.4) <0.0001 1.88 (0.6) 
Age (years), mean (SD) 80.0 (5.1)a,b 76.7 (4.9)c 75.0 (4.1) <0.0001 77.2 (5.1) 
White race (%) 122 (100) 128 (99.2) 120 (99.2) 0.38 370 (99.5) 
Body composition      
   Height (m), mean (SD) 171.5 (6.8)b 172.0 (6.7)c 173.9 (6.3) 0.01 172.5 (6.7) 
   BMI (kg/m2), mean (SD) 28.1 (3.7) 28.2 (3.6) 27.3 (3.5) 0.13 27.9 (3.7) 
   Fat mass (kg), mean (SD) 23.2 (6.6)b 22.7 (7.1) 21.3 (6.5) 0.09 22.4 (6.8) 
   Lean mass (kg), mean (SD) 55.6 (6.7)b 56.9 (7.5) 57.5 (6.6) 0.09 56.6 (7.0) 
   Muscle density (mg/cm3) 67.9 (4.6)a,b 69.4 (3.7) 70.4 (3.8) <0.0001 69.2 (4.2) 
Chronic health conditions      
   Diabetes, n (%) 25 (20.5) 20 (15.5) 16 (13.2) 0.25 63 (17.0) 
   AAI <0.9, n (%) 46 (42.6) 41 (34.2) 36 (30.3) 0.05 123 (35.5) 
   History of hypertension, n (%) 74 (60.7)b 66 (51.2) 50 (41.3) 0.003 190 (51.1) 
   History of stroke, n (%) 8 (6.7) 6 (4.7) 3 (2.5) 0.13 17 (4.6) 
   History of MI, n (%) 17 (13.9)a 31 (24.0) 18 (14.9) 0.84 66 (17.7) 
   History of CHF, n (%) 10 (8.2) 9 (7.0) 8 (6.6) 0.63 27 (7.3) 
   Hip pain, n (%) 19 (15.6) 24 (18.6) 16 (13.2) 0.62 59 (15.9) 
Lifestyle characteristics      
   History of smoking, n (%) 3 (2.5) 2 (1.6) 5 (4.1) 0.42 10 (2.7) 
   Physical Activity Score 
(PASE),  
   mean (SD) 
147.4 (65.8) 146.8 (64.6) 162.4 (65.2) 0.11 152.1 (65.4) 
SD = standard deviation; m = meters;  kg = kilograms;  PASE = Physical Activity Scale for the 
Elderly; ap<0.05 for  Lowest tertile vs. Middle tertile, bp<0.05 for Lowest tertile vs. Highest 
tertile, cp<0.05 for Middle tertile vs. Highest tertile 
 
 61 
Table 2.2 Nerve function by muscle power (watts/kg) tertiles 
Lowest tertile 
≤1.60 watts/kg 
(N=122) 
Middle tertile 
>1.60 and ≤2.06 
watts/kg  
(N=129) 
Highest tertile 
>2.06 watts/kg 
(N=121) 
p-value Total 
(N=372) 
Motor nerve conduction 
   Motor amplitude (mV), 
   mean (SD) 
2.15 (1.4)b 2.25 (1.4)c 2.84 (1.5) 0.0007 2.42 (1.5) 
   DML (ms), mean (SD) 4.33 (0.6) 4.42 (0.8) 4.49 (0.9) 0.34 4.41 (0.8) 
   Mean FWL (ms), mean (SD) 60.8 (6.6) 60.6 (5.8) 60.4 (5.5) 0.89 60.6 (5.9) 
Sensory nerve conduction 
   Sensory amplitude (μV), 
   mean (SD) 
3.07 (3.2)a,b 4.01 (3.4) 4.84 (3.7) 0.002 4.01 (3.4) 
   DSL (ms), mean (SD) 3.07 (2.9) 3.06 (0.2) 3.13 (0.3) 0.17 3.12 (0.4) 
Monofilament sensitivity, n (%) 
   1.4g sensitivity 51 (42.5)a,b 77 (60.2) 73 (60.3) 0.006 201 (54.5) 
   10g sensitivity 92 (76.7)a,b 110 (86.6) 104 (86.7) 0.04 306 (83.4) 
Neuropathic symptoms, n (%) 
   Numbness 45 (36.9)a 37 (28.9) 30 (24.8) <0.05 112 (30.2) 
   Pain 26 (21.5) 19 (14.8) 21 (17.5) 0.42 66 (17.9) 
   Open/persistent sore 4 (3.3) 2 (1.6) 2 (1.7) 0.39 8 (2.2) 
   One symptom 44 (36.4) 38 (29.9) 37 (31.2) 0.38 118 (32.4) 
   Two symptoms 15 (12.4) 8 (6.3) 7 (5.9) 0.06 30 (8.2) 
SD = standard deviation; m = meters;  kg = kilograms; mV = millivolts; DML = distal motor 
latency; ms = milliseconds; FWL = F-wave latency; DSL = Distal sensory latency; g = grams; 
ap<0.05 for  Lowest tertile vs. Middle tertile, bp<0.05 for Lowest tertile vs. Highest tertile, 
cp<0.05 for Middle tertile vs. Highest tertile 
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Table 2.3 Separate multivariate linear regression models for each measure of nerve function and muscle 
power (watts/kg) 
 1st Models 2nd Models 
 β (SE) R2 β (SE) R2 
Motor nerve function  
per SD lower 
    
   Motor amplitude -0.10‡ (0.03) 0.20 -0.07* (0.03) 0.29 
   Distal motor latency -0.05 (0.03) 0.17 -0.04 (0.03) 0.27 
   Mean F-wave latency 0.05 (0.03) 0.18 0.05 (0.03) 0.27 
Sensory nerve function  
per SD lower 
    
   Sensory amplitude  -0.10† (0.04) 0.20 -0.09* (0.04) 0.28 
   Distal sensory latency  -0.10 (0.34) 0.12 -0.06 (0.32) 0.21 
Monofilament insensitivity  
(yes/no) 
    
   1.4g -0.10 (0.06) 0.19 -0.11* (0.05) 0.28 
   10g -0.16* (0.07) 0.19 -0.17* (0.07) 0.29 
Neuropathic symptoms  
(yes/no) 
    
   Numbness -0.10 (0.06) 0.20 -0.09 (0.06) 0.28 
   Pain 0.01 (0.07)  0.04 (0.07)  
   Open sore -0.32 (0.18)  -0.36* (0.18)  
1st Models adjusted for age and height. 
2nd Models adjusted for variables in 1st Models plus total body lean and fat mass. 
SE = standard error; *P<0.05; †P<0.01; ‡P<0.001. 
 
Table 2.4 Separate multivariate linear regression models for each measure of nerve function and decline in 
muscle power (watts/kg) 
 Models 
 β (SE) R2 
Motor nerve function per SD lower   
   Motor amplitude 0.001 (0.04) 0.005 
   Distal motor latency -0.001 (0.03) 0.003 
   Mean F-wave latency 0.02 (0.04) 0.01 
Sensory nerve function per SD lower   
   Sensory amplitude  -0.05 (0.04) 0.01 
   Distal sensory latency  -0.06 (0.04) 0.03 
Monofilament insensitivity (yes/no)   
   1.4g 0.15* (0.07) 0.02 
   10g 0.11 (0.09) 0.01 
Neuropathic symptoms (yes/no)   
   Numbness 0.11 (0.07) 0.02 
   Pain -0.13 (0.09)  
   Open sore 0.15 (0.125)  
Models adjusted for age and height. 
SE = standard error; *P<0.05; †P<0.01; ‡P<0.001. 
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 Figure 2.1 Effect size of nerve conduction amplitudes and monofilament insensitivity compared to age 
Motor and sensory amplitude per standard deviation (SD) lower; 1.4-g and 10-g monofilament 
insensitivity (yes/no); age per year older; separate models adjusted for age, height, total body 
lean and fat mass; age adjusted for height, total body lean and fat mass; SD = Standard 
Deviation. 
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3.1 ABSTRACT 
Objective: To investigate the relationship between motor and sensory peripheral nerve function 
and longitudinal quadriceps strength in a large cohort of community dwelling older men and 
women. 
Design: Longitudinal cohort study. 
Setting: Two U.S. clinical sites. 
Participants: Eighteen hundred and thirty participants from the Heath Aging and Body 
Composition (Health ABC) Study (age = 76.3 ± 2.8 years, 51.0% female, 34.8% black, BMI= 
27.2 ± 4.6 kg/m2, strength = 96.1 ± 36.6 Nm). 
Measurements:  Our outcome was quadriceps strength measured using an isokinetic 
dynamometer at Years 4, 6, 8, and 10 of the study. Our predictors were nerve function measured 
at Year 4 and concurrent change in nerve function from Years 4 to 11 categorized as maintained 
normal, normal to poor, poor to normal, or sustained poor nerve function. Motor nerve 
conduction amplitude (poor <1 mV) and velocity (poor < 40 m/s) were measured on the deep 
peroneal nerve.  Sensory nerve function was assessed using 10-g and 1.4-g monofilaments and 
average vibration perception threshold.  Symptoms at the leg and feet (numbness or tingling; 
sudden stabbing, burning, pain or aches; and open or persistent sores) were assessed by self-
report. Adjusted models include age, height, total body lean and fat mass, diabetes, ankle-
brachial index, cerebrovascular disease, cardiovascular disease, knee pain, cognition, depression, 
vitamin B12 status, smoking, alcohol consumption, physical activity, and renal function. 
Results:  Poor initial 10-g monofilament detection was associated with 10.48 Nm lower 
strength (p<0.001) and 1.02 Nm faster strength decline ( p < 0.05) in women and 7.81 Nm lower 
strength (p < 0.05) in men. In the concurrent change analysis, sustained poor 10-g monofilament 
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sensitivity over seven years was associated with 15.88 Nm lower strength (p < 0.001) and 1.52 
Nm faster strength decline (p < 0.01). Poor 10-g monofilament sensitivity was associated with 
12.41 Nm lower strength, despite improving to normal by the end of seven years (p < 0.01). One 
SD worse initial average vibration detection threshold was associated with 2.81 Nm lower 
strength in men (p <0.01). In the concurrent change analysis, sustained poor  and declining from 
normal to poor vibration detection threshold over seven years were associated with 16.20 (p 
<0.01) and 10.29 (p <0.001) Nm lower strength, respectively. One SD worse initial motor 
amplitude and reporting two peripheral neuropathy symptoms were associated with 1.87 (p < 
0.01) and 5.97 (p < 0.01) Nm lower strength in women. In the concurrent change analysis, poor 
motor amplitude and symptoms were associated with 14.11 (p < 0.05) and 7.45 (p < 0.05) Nm 
lower strength despite improving to normal by the end of seven years. 
Conclusion:  In this cohort of older adults, poor initial and seven-year peripheral nerve 
function were associated with lower strength and a faster rate of strength decline, suggesting an 
important mechanism for late-life disability. Poor initial motor amplitude and symptoms 
predicted lower strength regardless of improvements by the end of seven years, suggesting that 
future work should investigate early prevention of modifiable risk factors and timely 
intervention. 
3.2 BACKGROUND 
Poor strength in late-life contributes to poor physical function,299,300 mobility disability,121,176,301 
hospitalization,302,303 and mortality.303-305 Given its major role in late-life disablement, 
investigating common risk factors and potential mechanisms for strength decline and disability in 
 67 
older adults is essential. 20 While sarcopenia, or muscle atrophy that occurs with age, plays a 
major role in declining strength, maintaining or gaining muscle mass does not guarantee 
prevention of strength loss with age,71 suggesting that other physiologic processes must be 
involved. One important mechanism for strength decline and incident disability that has been 
proposed is decline in peripheral nerve function.21 Impaired peripheral nerve function, which is 
highly prevalent23 in older adults both with and without diabetes mellitus, is associated with 
physical performance measures predictive of mobility disability8 in the Health, Aging and Body 
Composition (Health ABC) study.  
Cross-sectional evidence shows that peripheral nerve function is associated with 
diminished strength, independent of lean mass.21,159 Using data from the 2000-2001 (Year 4) 
visits in the Health ABC study, Strotmeyer and colleagues report that poor sensory and motor 
peripheral nerve function were related to lower quadriceps and ankle strength.21 However, the 
timing of the process is unclear. Using longitudinal data from this study cohort, we propose to 
further understand the importance of peripheral nerve function in longitudinal strength decline by 
examining: (1) the relationship between sensorimotor nerve function measured at one time point 
and subsequent longitudinal decline in lower extremity quadriceps strength over six years and; 
(2) the relationship between concurrent decline in sensorimotor nerve function and quadriceps 
strength.   
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3.3 METHODS 
3.3.1 Study participants 
The Health ABC Study is an ongoing prospective cohort study of well-functioning older adults 
(n = 3,075; 48.4% male; 41.6% black, ages 70-79 years at baseline) that was established in 1997-
1998 to investigate body composition and disability changes in older age.  Participants were 
recruited through mailings to a random sample of white Medicare beneficiaries and all black 
community residents eligible by age.  Eligibility, determined by phone interview, included 
having no difficulty walking a quarter of a mile, walking up 10 steps, or performing activities of 
mobility-related daily living, as well as having no life-threatening cancers with active treatment 
within the past 3 years, and planning to remain in the study area for at least 3 years.  Informed 
consent, provided prior to examination, was approved by the institutional review boards at the 
University of Pittsburgh and the University of Tennessee Health Science Center. Figure 3.1 
describes the number of participants that had nerve function and quadriceps strength measured at 
each visit. Compared to participants who returned for peripheral nerve exams seven years after 
the initial nerve exam, participants with missing data for the concurrent change in nerve function 
and strength analysis were older (76.8 vs. 76.1 years, p <0.0001), had lower BMI (26.7 vs. 27.5 
kg/m2, p = 0.0003), less fat mass (25.8 vs. 27.5 kg, p<0.0001), more peripheral arterial disease 
(18.6% vs. 11.2%, p < 0.0001), worse sensory nerve function (monofilament insensitivity: 10.1% 
vs. 6.8%, p = 0.01; vibration perception: 52.7 vs. 48.2 µ, p < 0.01), and lower strength (92.9 vs. 
98.0 Nm, p = 0.002). Other factors (sex, race, diabetes prevalence, smoking status, alcohol 
consumption, knee pain, blood pressure, motor nerve conduction, lean mass, physical activity) 
were not different.  
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3.3.2 Quadriceps strength 
Quadriceps strength was measured concentrically at 60° per second from 90° to 30° using a Kin-
Com isokinetic dynamometer (Harrison, TN) at Years 4, 6, 8, and 10 on the right leg, unless the 
participant had a knee replacement or knee pain. Following a warm up at submaximal effort, 
participants performed three to six trials, and the mean maximal torque from the three best trials 
was calculated. Contraindications for this test included history of brain aneurysm or stroke, 
bilateral knee replacement, severe bilateral knee pain, systolic blood pressure greater than 199 
mmHg and diastolic blood pressure greater than 109 mmHg. Individuals with contraindications 
are labeled as “excluded” in Figure 3.1. 
3.3.3 Sensory and motor peripheral nerve function 
Peripheral nerve function was measured at Years 4 and 11 of the Health ABC study as 
previously described.65 Each study site (Memphis and Pittsburgh) had a clinic staff examiner 
trained by a technician experienced in clinical trials using NC measures as outcomes and a board 
certified neurologist with additional certifications in electrodiagnostic medicine and 
neuromuscular medicine, qualifications in clinical neurophysiology, and specialization in 
neuromuscular disorders. After warming the feet to 30°C, measures were performed on the right 
leg unless contraindicated because of knee replacement, amputation, trauma, ulcer, or surgery. If 
the right leg was contraindicated, measures were performed on the left leg, unless it too was 
contraindicated. Peroneal motor nerve conduction amplitude and velocity were measured from 
the popliteal fossa to the ankle using the NeuroMax 8 (XLTEK, Oakville, Ontario, Canada). 
Sensory nerve function was measured using average vibration detection threshold on the bottom 
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of the large toe with a VSA-3000 Vibratory Sensory Analyzer (Medoc, Ramat Yishai, Israel). 
Monofilament insensitivity, defined as the inability to detect three out of four touches, was 
measured at the dorsum of the large toe with a 10-g standard monofilament and a 1.4-g light 
monofilament. Number of self-reported peripheral neuropathy symptoms were collected and 
coded from 0-3; these include having (1) numbness or tingling, (2) sudden stabbing, burning, 
pain or aches, and (3) an open or persistent sore, or gangrene on either feet or leg, all in the past 
12 months.  
For the concurrent change analysis, participants were divided into one of four categories: 
(1) maintained normal; (2) normal to poor; (3) poor to normal; and (4) sustained poor. Poor 
nerve function was categorized using clinical cut points of <1 mV for motor amplitude and <40 
m/s for motor nerve conduction velocity. Poor nerve function was also defined as 1.4-g and 10-g 
touch monofilament insensitivity, lack of detection of a maximum vibration perception threshold 
(>131 μ), and reporting 2 peripheral neuropathy symptoms. Participants who experienced <5% 
of continuous change for amplitude, velocity, or vibration perception threshold were not 
considered to have transitioned from normal to poor or from poor to normal. 
3.3.4 Additional covariates 
We considered severel factors known or hypothesized to be associated with nerve function and 
lower extremity strength and function. Height and weight were measured using a stadiometer and 
a calibrated balance beam scale. Whole body bone-free lean and fat mass were measured using 
dual-energy X-ray absorptiometry (DXA; Hologic 4500A, Hologic, Inc., Bedford, MA). 
Diabetes was defined as self-report of physician diagnosis, hypoglycemic medication use, or 
fasting glucose greater than 126 mg/dL (47.0 mmol/L) and impaired fasting glucose was defined 
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at 100 mg/dL to <126 mg/dL  after an 8-hour or longer fast.306 Hypertension was assessed by 
self-report, medication use, and diastolic blood pressure ≥ 90 mmHg or systolic blood pressure ≥ 
140 mmHg. A >1 drink/week cutpoint for alcohol consumption was used. Ankle brachial index 
cutpoints were used to indicate peripheral arterial disease (<0.9) and arterial stiffening (≥ 1.3). 
Depressive symptoms were measured using an interviewer-administered Center for 
Epidemiologic Studies Depression Scale.307 We measured cognitive function using the Modified 
Mini-Mental State Examination (3MSE), and attention, psychomotor speed, and executive 
function using the Digit Symbol Substitution Test (DSST).308 Insufficient renal function was 
defined as Cystatin-C > 1mg/dL.309 Self-reported knee pain on most days in the past 12 months 
was assessed. We defined poor vitamin B12 status as < 260 pmol/L.249 Prevalent cerebrovascular 
disease(transient ischemic attack or stroke), cardiovascular disease (bypass or coronary artery 
bypass graft, carotid endarterectomy, myocardial infarction, angina pectoris, congestive heart 
failure), knee pain, Cystatin-C, alcohol consumption, and DSST were measured at baseline 
(1997/1999). Smoking status and 3MSE were measured at Year 3 (1999/2000). All other 
covariates were measured during the Year 4 nerve exam (2000/2001). Body weight, total lean 
mass, total fat mass, and weekly physical activity spent walking and climbing stairs 
(kcal/kg/week) were included as a time varying covariates from Years 4, 6, 8, and 10. 
3.3.5 Statistics 
Since men and women differ greatly in muscle strength and body composition, means and 
frequencies of participant characteristics were compared between men and women using t-test 
and chi-squared statistics. Mixed linear models were used to assess the relationships between 
initial and concurrent change in nerve function and strength to maximize the use of all available 
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time points of strength data and to account for the correlation between repeated measures. We 
included participants that had at least two measures of strength with one measure occuring at 
Year 4. Most participants had all four strength measures (n=1110), although some only had two 
(n=349) or three (n=371). Strength was entered as a time varying outcome in the models. The 
beta value for the main effect of each predictor represents the magnitude of the effect on strength 
over all available timepoints. The beta value for the interaction between time and each predictor 
is the magnitude of the effect on rate of decline in strength. Separate models were built for each 
measure of nerve function since some were moderately correlated (motor amplitude and 
conduction velocity: r=0.33, p<0.0001) and each represents a different aspect of peripheral nerve 
function. The first set of models started with baseline nerve function then were minimally 
adjusted for age, race, height, weight, study site, and the interaction between each variable and 
time. Then models were additionally adjusted for lean and fat mass instead of weight, given their 
relationship with strength and physical function,71,310 and to assess whether lean mass mediated 
the relationship between nerve function and strength. Additional variables were added to the 
final models if they were related to the initial predictor or outcome at an alpha level <0.1. Fully 
adjusted models included diabetes, ankle brachial index, cerebrovascular disease, cardiovascular 
disease, knee pain, cognition, depression, vitamin B12 status, smoking, alcohol consumption, 
physical activity, and renal function, unless removed due to a p-value >0.1 to prevent 
collinearity.  We also tested interactions between sex and nerve function measures to assess 
whether sex modified the relationship between nerve function and strength.  In addition, due to 
the known effect of diabetes on peripheral nerve function and muscle strength,251,252 we ran a 
sensitivity analysis excluding all cases of diabetes. 
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3.4 RESULTS 
Table 3.1 compares characteristics between men and women. Men had greater quadriceps 
strength, height, lean mass, and fat mass. They were more likely to consume >1 drink/week and 
had higher physical activity levels. Men also had higher rates of diabetes, impaired fasting 
glucose, arterial stiffening, cardiovascular disease, and poor vitamin B12 status. Men had worse 
sensory and motor nerve function, but women reported more peripheral neuropathy symptoms 
(Table 3.2). Figure 3.1 shows the percentage and number of participants in each nerve change 
group.  Significant and borderline significant interactions between sex and initial average 
vibration detection threshold (p = 0.01) and motor amplitude (p = 0.09) were associated with 
strength; therefore analysis for initial nerve function and strength were performed separately in 
women (Table 3.3) and men (Table 3.4). The analysis assessing relationships between concurrent 
change in nerve function and strength were not stratified by sex since there were no significant 
interactions between nerve function change and sex. All beta values for continuous predictors are 
standardized. 
Initial 1.4-g and 10-g monofilament insensitivity were associated with 2.72 and 10.48 
Newton meters (Nm) lower strength in women and 4.94 and 7.81 Nm lower strength in men. In 
the concurrent change analysis (Table 3.5), maintaining poor 10-g and 1.4-g sensitivity over 
seven years were associated with 15.88 and 5.31 Nm lower strength, respectively, although the 
association with 1.4-g sensitivity was attenuated to nonsignificant after further adjustment for 
comorbid conditions, lifestyle factors, and cognition (results not shown). Poor 10-g 
monofilament sensitivity was associated with 12.42 Nm lower strength, despite improving to 
normal by the end of seven years. Initial 10-g monofilament insensitivity was related to 
increased strength decline in women, as was maintaining poor 10-g monofilament sensitivity in 
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the concurrent change analysis. In men, worse initial average vibration detection threshold was 
associated with 2.81 Nm lower strength, but not in women. Declining from normal to poor and 
sustaining poor average vibration detection threshold over seven years was also associate with 
10.29 and 16.20 Nm lower strength, respectively in the concurrent change analysis. In women, 
lower initial motor amplitude and reporting two peripheral neuropathy symptoms were 
associated with 1.87 and 5.97 Nm lower strength but not in men. Despite improving to normal 
over the seven year period, starting with poor motor amplitude and peripheral neuropathy 
symptoms remained associated with 14.11 and 7.45 Nm lower strength. In women, initially 
reporting one peripheral neuropathy symptom was associated with greater strength decline, as 
was transitioning from reporting two to reporting less than two symptoms over the seven year 
period, but both were attenuated to nonsignificant when adjusting for comorbid conditions, 
lifestyle factors, and cognition (results not shown).  When we excluded participants with 
diabetes, 1.4-g monofilament insensitivity was no longer a significant predictor of strength in 
men or in the concurrent change analysis. Also going from reporting less than two to reporting 
two peripheral neuropathy symptoms (normal to poor) was associated with lower strength, 
whereas the other symptom groups were not. All other associations remained consistent. 
3.5 DISCUSSION 
Using prospective data from this large cohort of older men and women, we were able to 
characterized neuromuscular decline in late-life using multiple clinical measures of peripheral 
neuropathy. We found that poor peripheral nerve function at one time point and over seven years 
were associated with low concurrent strength and strength decline. These findings are important 
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because they confirm key mechanisms for strength decline, which contribute to poor 
function,299,300 disability,121,301 and other major health outcomes302-305 in older adults. Clearly 
factors other than decline in lean mass contribute to strength loss,21,71 yet prior to this, the 
complex longitudinal relationship between strength and measures of motor and sensory nerve 
function had not been demonstrated in an aging cohort. 
In our study population, Strotmeyer and colleagues21 found that both sensory and motor 
nerve function measures were cross-sectionally associated with strength. The mechanisms for 
sensory and motor nerve involvement are undoubtedly different and our longitudinal data offers 
some insights.  Motor nerves carry signals to the muscles and are responsible for movement, 
while sensory nerves carry external stimuli to the brain or spinal cord. Afferent (sensory) input 
may be necessary to achieve proper placement, timing, and movement of the leg during testing, 
since severe sensory neuropathy has been associated with poor ankle proprioception.295,296 
Moreover, experimentally blocking afferent input in healthy individuals has led to reduced 
maximal voluntary contractions13 and suggests a direct relationship with strength. Consistent 
with findings from our previous work, motor amplitude, but not nerve conduction velocity was 
related to quadriceps strength. Low motor amplitude indicates axonal degeneration of the nerve, 
while low nerve conduction velocity indicates demyelination. Our findings implicate axonal 
degeneration in the pathology of neuromuscular weakness, particularly in women, but do not 
discount the important role of sensory afferents.  
Motor and sensory nerve function at the initial time point predicted six-year muscle 
strength in women, whereas only sensory nerve function predicted strength in men. In the 
concurrent change analysis, poor sensory nerve function over time was consistently associated 
with poor strength. While early poor function seemed critical for motor amplitude and peripheral 
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neuropathy symptoms, transitioning to poor function seemed to be the key for vibration 
perception threshold. Given that these measures of nerve function are not highly correlated and 
each capture distinct physiologic aspects of the peripheral nervous system and the neuropathic 
process, it is not surprising that these different relationships with muscle strength were observed. 
We also investigated the role of lean mass in these relationships. Peripheral neuropathy 
may include symptoms of weakness and muscle wasting in severe cases.311 In addition, muscle 
tissue from individuals with clinical neuropathy can be characterized by smaller atrophied fibers. 
34 Although, Lauretani and colleagues found that neither motor amplitude nor nerve conduction 
velocity were associated with lean mass cross-sectionally.33 In our study, although lean mass was 
associated with strength, it did not mediate the relationship between peripheral nerve function 
and strength. Previous work has found a cross-sectional relationship between muscle density (a 
measure of intermuscular fat) and motor amplitude; therefore future work should examine 
muscle density as a potential mediator. 
Consistent  with our previous findings, we found that, compared to women, men had 
worse peripheral nerve function for all measures.21 Slower nerve conduction velocity in men can 
be attributed to greater height.111 We also found that men in our study population had higher 
rates of known risk factors for peripheral neuropathy such as diabetes, impaired fasting glucose, 
and vitamin B12 deficiency.249 Additional disparity may be attributable to increased clinical and 
subclinical cardiovascular disease in men312 and its effects on peripheral nerve function.100,313 
Although we adjusted for cardiovascular disease, blood pressure, ankle brachial index, and 
smoking we may not have fully captured all of the subclinical cardiovascular effects on 
peripheral nerve function. It is somewhat counterintuitive that while women tend to have better 
nerve function, they experience more late-life disability.101-103 Since men tend to have 
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significantly more muscle mass and strength throughout life than women, 58 one hypothesis is 
that women, lacking this additional strength, are more susceptible to the negative effects of poor 
nerve function. Future studies are needed to investigate these neuromuscular sex differences, 
particularly given their likely connection to late-life disability.  
This study had a number of strengths. Both sensory and motor nerve function were 
assessed using clinical methodology. Our measures of motor nerve function are gold standard 
clinical measures of peripheral neuropathy that have been found to be highly reproducible in a 
subset of older adults from this study cohort with interclass correlation coefficients (ICCs) of 
0.90-0.99 and coefficients of variation of 2.15-4.24.65 We used multiple years of prospective data 
from a large, multiethnic, well-characterized cohort of older men and women. We assessed 
change in nerve function using clinical cutpoints.314 For categories created from continuous 
measures (motor amplitude, conduction velocity, and vibration perception) individuals with 
marginal change (<5%) were not considered to have transitioned from normal to poor or poor to 
normal, preventing those with minimal changes from biasing our results. 
Moreover, our nerve change categories allowed for all directions of change, including 
improvement. The number of participants with improved nerve function depended on the method 
of measurement and ranged from n = 13 for motor amplitude to n = 179 for 1.4-g monofilament 
sensitivity. One potential reason for nerve function improvement may be neuroplasticity of 
newly mildly impaired nerves, since nerves that experience early mild damage are more likely to 
regain some function.315,316 We found that the majority of participants improved on a more 
sensitive measure of nerve function, supporting this hypothesis. Another potential reason for 
improvement is better control of diabetes. Twenty percent of participants in this analysis had 
diabetes at the initial nerve exam of the study. Early intervention for diabetic and prediabetic 
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individuals can slow the progression of and may even improve peripheral neuropathy.317-320 An 
additional reason for improvement of nerve function could be treatment for vitamin B12 
deficiency.249,250 However, our data is limited in that we do not know when these improvements 
occurred. These findings may be evidence of neuroplasticity of peripheral nerves in older adults, 
and warrant further study. Our finding that individuals improving to normal motor amplitude and 
experiencing reduced symptoms had worse strength may be evidence of the negative and lasting 
effects of early nerve function impairments and suggest the importance of early prevention and 
intervention, such as better glycemic control or supplementation for a vitamin B12 
deficiency.249,250 
Diabetes may still have independent effects on muscle strength. We found that in men, 
diabetes remained a significant predictor of poor strength in models with sensory nerve function 
measured at the initial time point, while impaired fasting glucose remained a significant predictor 
of strength decline in models with motor amplitude and nerve conduction velocity. In women, 
diabetes remained a significant predictor of strength decline in models with symptoms and 
average vibration detection threshold. Our results, however, were mostly consistent when we 
excluded individuals with diabetes in our sensitivity analysis, suggesting that the relationships 
we found were not driven by diabetes alone.  This is consistent with what we found in our 
previous cross-sectional study21 and is likely explained by the high prevalence of impaired nerve 
function that has been found in older adults without diabetes.23  
One limitation is that we may have had insufficient statistical power to detect 
associations between strength and some nerve function change groups due to small numbers of 
observations in the groups. In addition, these small numbers may have prevented us from 
detecting sex as a modifier in the relationship between change in nerve function and strength. 
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Furthermore, participants who returned for follow up clinic visits were somewhat healthier than 
those without missing data, resulting in some inevitable retention bias.321  
In conclusion, poor motor and sensory nerve function contribute to poor and declining 
strength in older adults.  Given the high incidence and prevalence of subclinical and overt 
neuropathy in older adults,22,23 and the current and projected future diabetes epidemic,322 
identifying associated risks and outcomes of poor nerve function such as muscle weakness and 
declines in strength is essential. Poor nerve function is likely to play an important role in the 
pathway to disability and future work should focus on this area. Modifiable risk factors and 
interventions for neuromuscular decline in late-life and optimal timing for adminstering these 
intervention are understudied areas that need to be investigated. 
Figure 3.1 Participants with strength & nerve function 
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Figure 3.2 Percent of participants in each nerve change group 
Poor nerve function defined as <1 mV for motor amplitude, <40 m/s for velocity, lack of 
detection of 3 out of 4 touches with 1.4-g and 10-g monofilaments, lack of detection of >131 µ 
of vibration, reporting 2 or more peripheral neuropathy symptoms. 
Table 3.1 Participant characteristics by sex 
Characteristics Women 
n = 934 
Men 
n = 896 
p-value 
Age, years 76.2 (2.8) 76.5 (2.8) 0.005 
Black race, n (%) 367 (39.3) 270 (30.1) <0.0001 
Quadriceps strength, Nm 74.0 (21.0) 119.1 (30.8) <0.0001 
Body composition 
    Height, cm 158.1 (15.0) 172.8 (8.8) <0.0001 
    BMI, kg/m2 27.2 (5.3) 27.1 (3.8) 0.56 
    Lean mass, kg 40.8 (6.1) 56.3 (7.2) <0.0001 
    Fat mass, kg 28.7 (9.1) 25.1 (7.2) <0.0001 
Lifestyle characteristics 
    Current smoker, n (%) 58 (6.5) 56 (6.5) 0.99 
    Alcohol consumption > 1/week, n (%) 424 (46.1) 526 (59.7) <0.0001 
    Physical activity, kcal/kg/week 5.0 (15.5) 6.9 (13.6) 0.004 
Chronic health conditions 
    Diabetes, n (%) 161 (17.4) 211 (23.9) 0.0006 
    Impaired fasting glucose, n (%) 118 (12.8) 174 (19.7) <0.0001 
    Ankle-arm index <0.9, n (%) 126 (14.0) 120 (13.8) 0.90 
    Ankle-arm index >1.3, n (%) 30 (3.3) 63 (7.2) 0.0002 
    Hypertension, n (%) 745 (80.8) 695 (78.5) 0.23 
    Cardiovascular disease, n (%) 84 (9.7) 191 (23.0) <0.0001 
    Cerebrovascular disease, n (%) 53 (5.8) 45 (5.2) 0.54 
    Knee pain most days per month, n (%) 153 (16.6) 124 (14.0) 0.13 
    Poor vitamin B12, n (%) 128 (14.4) 177 (20.3) 0.001 
Data are means ± SD unless otherwise specified 
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 Table 3.2 Initial peripheral nerve characteristics by sex 
Peripheral nerve characteristics at Year 4 Women  
n = 934 
Men  
n = 896 
p-value 
Motor nerve function    
   Amplitude, mV  3.7 (2.0) 3.1 (1.9) <0.0001 
   Conduction Velocity, m/s 45.3 (5.3) 41.9 (4.9) <0.0001 
Sensory nerve function    
   1.4g monofilament insensitivity, n (%) 348 (37.7) 446 (50.4) <0.0001 
   10g monofilament insensitivity, n (%) 49 (5.3) 95 (10.8) <0.0001 
   Vibration threshold, μ 42.7 (31.4) 57.4 (36.4) <0.0001 
Peripheral nerve symptoms    
   Numbness, n (%)  273 (29.5) 217 (24.3) 0.01 
   Pain, n (%) 173 (18.7) 106 (11.8) <0.0001 
   Two, n (%) 94 (10.1) 55 (6.14) 0.002 
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Table 3.3 Initial nerve function predicts longitudinal quadriceps strength in women 
 1st Models 2nd Models 3rd Models 
 Betas Betas Betas 
 Main effect Time 
interaction 
Main effect Time  
interaction 
Main effect Time  
interaction 
Motor nerve function       
   Amplitude, SD lower -2.31‡ -0.09 -2.35‡ -0.07 -1.87† 0.11 
   Velocity, SD lower -0.29 -0.07 -1.30 -0.04 0.24 -0.11 
Sensory nerve function       
   1.4-g monofilament  
   insensitivity 
-3.03* 0.14 -2.68* 0.05 -2.72* 0.12 
   10-g monofilament  
   insensitivity 
-10.65§ 1.14* -11.61§ 1.12* -10.48‡ 1.02* 
   Vibration perception  
   threshold 
-0.03 -0.04 -0.84 0.03 0.45 -0.01 
Symptoms       
   One -0.64 0.52* -0.64 0.46* 0.06 0.35 
   Two -6.54† 0.65 -7.05‡ 0.64 -5.97† 0.44 
SD = standard deviation 
*P<0.05; †P<0.01; ‡P<0.001; §P<0.0001. 
1st Models – adjusted for age, race, height, weight, site, time interactions 
2nd Models – 1st Models + lean & fat mass instead of weight 
3rd Models:  
Motor nerve function – 1st Models + low and stiffening AAI, knee pain, DSST, CES-D, 
smoking, physical activity, renal function 
Sensory nerve function – 1st Models + diabetes, low and stiffening AAI, knee pain, DSST, 
CES-D, smoking, physical activity, renal function 
Symptoms – 1st Models + low and stiffening AAI, knee pain, DSST, CES-D, smoking, physical 
activity, renal function 
 
Table 3.4 Initial nerve function predicts longitudinal quadriceps strength in men 
 1st Models 2nd Models 3rd Models 
 Betas Betas Betas 
 Main effect Time 
interaction 
Main effect Time  
interaction 
Main effect Time 
 interaction 
Motor nerve function       
   Amplitude, SD lower -1.96 0.28 -1.60 0.30 -1.24 0.26 
   Velocity, SD lower 0.01 0.27 0.33 0.16 0.69 0.33 
Sensory nerve function       
   1.4-g monofilament  
   insensitivity 
-5.24† -0.15 -4.73†  -0.35 -4.94† 0.05 
   10-g monofilament  
   insensitivity 
-9.23† 0.31 -8.95† 0.12 -7.81* 0.50 
   Vibration perception  
   threshold 
-3.75§ 0.08 -4.41§ 0.16 -2.81† 0.01 
Symptoms       
   One -1.29 -0.42 -0.26 -0.22 0.44 -0.58 
   Two -1.73 0.11 -2.28 0.63 1.48 0.02 
SD = standard deviation 
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*P<0.05; †P<0.01; ‡P<0.001; §P<0.0001. 
1st Models – adjusted for age, race, height, weight, site, time interactions 
2nd Models – 1st Models + lean & fat mass instead of weight 
3rd Models:  
Motor nerve function – 1st Models + low and stiffening AAI, stiffening AAI, cerebrovascular 
disease, knee pain, poor vitamin B12, DSST, CES-D, renal function 
Sensory nerve function – 1st Models + diabetes, cerebrovascular disease, knee pain, DSST, 
CES-D, renal function 
Symptoms – 1st Models + diabetes, cerebrovascular disease, knee pain, DSST, CES-D, renal 
function 
 
 
Table 3.5 Seven-year change in nerve function predicts concurrent longitudinal quadriceps strength 
 Maintained 
normal 
Normal to poor Poor to normal Sustained poor 
  Betas Betas Betas 
Motor nerve function  Main  
effect 
Time 
interaction 
Main  
effect 
Time 
interaction 
Main  
effect 
Time 
interaction 
   Amplitude REF -0.11 -0.25 -14.11* 1.51 -5.46 0.64 
   NCV REF 2.59 -0.43 3.24 -0.51 2.84 0.01 
Sensory nerve function        
   1.4-g monofilament  
   sensitivity 
REF 1.34 -0.14 -3.12 -0.01 -5.31† -0.05 
   10-g monofilament  
   sensitivity 
REF -1.29 -0.11 -12.42† 0.64 -15.88‡ 1.52† 
   Vibration perception  
   threshold 
REF -10.29‡ 0.57 -6.18 0.95 -16.20† -0.19 
Two symptoms REF -2.31 0.07 -7.45* 1.04* -3.78 0.29 
Model adjusted for age, race, height, lean and fat mass, site, time interactions; 
Poor nerve function defined as <1 mV for motor amplitude, <40 m/s for velocity, lack of 
detection of 3 out of 4 touches with 1.4-g and 10-g monofilaments, lack of detection of >131 µ 
of vibration, reporting 2 or more peripheral neuropathy symptoms. 
*P<0.05; †P<0.01; ‡P<0.001; §P<0.0001. 
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4.1 ABSTRACT 
Importance: Poor peripheral nerve function, which is highly prevalent in older adults, is 
associated worse lower extremity function and limitation. Although, longitudinal evidence is 
needed to elucidate sensory and motor nerve function’s role in mobility disability. 
Objective: To assess the relationship between sensory and motor nerve function over 7 
years and incident mobility limitation over of 8.5 years (IQR: 4.5-9.6). 
Design: Longitudinal analysis in the Health, Aging, and Body Composition (Health 
ABC) Study, a prospective cohort study designed to assess body composition and its effects on 
mobility limitation. 
Setting: Two U.S. clinical sites. 
Participants: Population-based sample of community-dwelling men and women with no 
mobility limitation at baseline (N=1680, age=76.5±2.9, BMI=27.1±4.6, 50.2% women, 36.6% 
black, 10.7% with diabetes; 30% developed limitation).  
Exposures: Our predictors were nerve function measured at Year 4 and change in nerve 
function from Years 4 to 11 categorized as maintained normal, normal to poor, poor to normal, 
or sustained poor nerve function. Motor nerve conduction amplitude (poor <1 mV) and velocity 
(poor < 40 m/s) were measured on the deep peroneal nerve.  Sensory nerve function was 
measured using 10-g and 1.4-g monofilaments and vibration detection threshold.  Self-reported 
symptoms were assessed at the leg and feet and included numbness or tingling, sudden stabbing, 
burning, pain or aches, and open or persistent sores.  
Main Outcomes and Measures: Incident mobility limitation was measured 
semiannually over 10 years after the initial nerve function exam and was defined as two 
consecutive self-reports of a lot of difficulty or inability to walk a ¼ of a mile or climb 10 steps. 
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Models were adjusted for age, sex, race, study site, body composition, diabetes, ankle arm index, 
cerebrovascular disease, knee and hip pain, osteoporosis, depression, smoking, alcohol 
consumption, vitamin B12 status, physical activity, and renal function. 
Results: Initial (HR = 1.26 per SD, 95% CI: 1.12-1.41) and sustained poor motor 
amplitude over seven years (HR = 3.56, 95% CI: 1.63-7.76) were independently associated with 
incident mobility limitation. Worse initial sensory nerve function measured using vibration 
detection threshold (HR = 1.11, 95% CI: 1.01-1.22) and self-reported symptoms (HR = 1.47, 
95% CI: 1.09-1.99) also predicted mobility limitation. 
Conclusions and Relevance: In this cohort of older adults, poor motor and sensory nerve 
function were independently associated with incident mobility limitation, with the strongest 
hazard ratio for sustained poor motor amplitude over time. These findings suggest a role in the 
causal pathway towards mobility disability. 
4.2 BACKGROUND   
Poor motor and sensory peripheral nerve function are associated with measures of lower 
extremity function,20,27,28  including gait speed, balance, chair stands, and muscle strength in 
older adults both with and without diabetes. These measures of physical function are predictive 
of activities of daily living (ADL) and mobility disability,8 suggesting that poor nerve function 
may play a role in the late-life disablement process. Moreover, evidence shows that sensory 
measures and neurological signs are associated with mobility limitations.28,31 These findings 
have critical implications for older adults, since they experience the highest burden of both poor 
nerve function and disability.4,22,23 
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While the cross-sectional evidence suggests that motor and sensory nerve function may 
be an important risk factor for disability, quantification of their relationship with incident 
mobility limitation is lacking. This longitudinal investigation will help elucidate the potential 
etiologic role of nerve function in the disablement process. We assessed whether initial and 
change in sensory and motor peripheral nerve function measured at two time points, seven years 
apart, predicted incident mobility limitation in a cohort of community dwelling older adults.  
4.3 METHODS 
4.3.1 Study participants 
The Health, Aging, and Body Composition (Health ABC) Study is an ongoing prospective 
cohort study established in 1997-1998 to study the long-term effects of body composition on 
disability changes in older adults (n = 3,075; 48.4% male; 41.6% black, ages 70-79 years at 
baseline). Participants were recruited by mail to a random sample of white Medicare 
beneficiaries and all black community residents eligible by age. Eligibility was determined by 
phone interview and included having no difficulty walking a quarter of a mile or walking up 10 
steps, having no difficulty performing mobility-related activities of daily living, having no life-
threatening cancers with active treatment within the past 3 years, and planning to remain in the 
study area for the next 3 years. Participants included in the initial nerve (Figure 4.1) had at least 
one nerve function measure performed at Year 4 (2000/01) of the study and no mobility 
limitation prior to Year 4 (n = 2148). Participants in the nerve change analysis had nerve 
function measured at Year 4 and Year 11 and no mobility limitation prior to Year 11 (n = 977). 
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4.3.2 Mobility limitation 
Mobility limitation was assessed semiannually during clinic visits or over the phone by either the 
participant or an identified proxy.  Persistent mobility limitation was defined as two consecutive 
self-reports of a lot of difficulty or inability to walk a ¼ of a mile or climb 10 steps and will be 
referred to as mobility limitation for simplicity. For the initial nerve analysis, time to event was 
calculated as the time from the Year 4 (2000/01) nerve function exam to the first self-report of 
mobility limitation out of the two consecutive reports. For the nerve change analysis, time to 
event was calculated as time from the Year 11 (2008/09) nerve function exam to the first report 
out of two consecutive. Participants who did not experience mobility limitation were censored at 
their last date of contact or at death. If death was preceded by one or more missed contacts, 
information from the decedent proxy interview was used to determine any incident mobility 
limitation. The proxy’s estimated date of onset was compared to the visit window for the missed 
contact and if the reported onset occurred before the end of the visit window, the incident 
limitation was assigned to that contact. 
4.3.3 Peripheral nerve function 
Peripheral nerve function was measured at Years 4 (2000/01) and 11 (2008/09) of the Health 
ABC study by a trained and certified clinic examiner as described previously.65 After the feet 
were warmed to 30°C, measures were performed on the right leg unless contraindicated because 
of knee replacement, amputation, trauma, ulcer, or surgery. If the right leg was contraindicated, 
measures were performed on the left leg, unless it too was contraindicated. Peroneal motor nerve 
conduction velocity and amplitude were measured after nerve stimulation at the popliteal fossa, 
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fibular head and the ankle using the NeuroMax 8 (XLTEK, Oakville, Ontario, Canada). Sensory 
nerve function was measured using vibration detection threshold on the bottom of the large toe 
with a VSA-3000 Vibratory Sensory Analyzer (Medoc, Ramat Yishai, Israel). Monofilament 
insensitivity, defined as the inability to feel three to four touches, was measured at the dorsum of 
the large toe with a 10-g standard monofilament and a 1.4-g light monofilament. Number of self-
reported peripheral neuropathy symptoms were collected and coded from 0-3; these include 
having (1) numbness or tingling, (2) sudden stabbing, burning, pain or aches, and (3) an open or 
persistent sore, or gangrene on either feet or leg, all in the past 12 months. For the nerve change 
analysis participants were divided into one of four categories: (1) maintained normal; (2) normal 
to poor; (3) poor to normal; and (4) sustained poor. We used clinically meaningful cut points of 
<1 mV for motor amplitude and <40 m/s for motor nerve conduction velocity (NCV) to define 
poor nerve function. Poor nerve function was also defined as 1.4-g and 10-g touch monofilament 
insensitivity, lack of detection of a vibration threshold >131 μ, and reporting 2 or more 
peripheral neuropathy symptoms. Participants were only classified as normal to poor or poor to 
normal if they had >5% for continuous nerve function measures of amplitude, velocity, or 
vibration detection. For example a participant with a poor Year 11 motor amplitude that was 
<5% lower that his normal Year 4 motor amplitude would be categorized as maintained normal 
rather than normal to poor. 
4.3.4 Additional covariates 
We considered several factors known or hypothesized to be associated with both poor nerve 
function and incident mobility disability. All covariates were measured at the initial Year 4 nerve 
exam (2000/01), unless otherwise noted. We included demographics characteristics of age, sex, 
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race, and study site. Standing height was measured using a stadiometer and weight was measured 
using a calibrated balance beam scale at the initial nerve exam. Dual-energy X-ray 
absorptiometry (DXA; Hologic 4500A, Hologic, Inc., Bedford, MA) was used to measure total 
body bone-free lean and fat mass. Diabetes was defined as self-reported physician diagnosis, 
hypoglycemic medication use, or fasting glucose greater than 126 mg/dL [47.0 mmol/L] after an 
8-hour or longer fast.306 Ankle arm index (AAI) <0.9 was used to indicate peripheral arterial 
disease and >1.3 was used to indicate arterial stiffening. Hypertension was determined by self-
report, medication use, and diastolic blood pressure ≥ 90 mmHg or systolic blood pressure ≥ 140 
mmHg. Prevalent cardiovascular disease (bypass/coronary artery bypass graft, carotid 
endarterectomy, myocardial infarction, angina, or congestive heart failure), cerebrovascular 
disease (transient ischemic attack or stroke), and osteoporosis were assessed at the 1997/98 visit. 
Participants were also asked whether they experienced knee or hip pain on most days or for at 
least one month in the past 12 months (1997/98). The Center for Epidemiolgic Studies 
Depression Scale Depression (CES-D), which was interviewer administer, was used to assess 
depressive symptoms. Poor vitamin B12 status was defined as < 260 pmol/L.249 Smoking status 
(current/past) was measured during the 1999/00 visit and alcohol consumption (<1 drink/week) 
was measured during the 1997/98 visit. Physical activity was estimated as kcal/kg/week spent 
walking and stair climbing using a questionnaire. Poor renal function was defined as Cystatin-C 
> 1mg/dL (1997/98). Cognitive function was measured with the Modified Mini-Mental State 
Examination (3MSE) (1999/00), and attention, psychomotor speed, and executive function was 
measured with the Digit Symbol Substitution Test (DSST) (1997/98).308  
For the nerve function change analysis, time varying covariates were entered into the 
models. Based on their relationship with mobility, these included weight or lean and fat mass 
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entered in place of weight,176,290 weight change,323 calculated using weight from the previous 
clinic visit, knee and hip pain,324 physical activity,325,326 and psychometric measures such as 
CES-D,327 3MSE,327,328 and DSST scores.329 Diabetes, impaired fasting glucose,330 and AAI,255 
were also entered as time varying, since these variables are closely related to nerve function. 
4.3.5 Statistics 
Means and frequencies of baseline characteristics were calculated and assessed as potential risk 
factors for incident mobility limitation using bivariate Cox proportional hazards regression. 
Multivariable Cox proportional hazards regression was used to model the relationships between 
time to mobility limitation and initial and change in nerve function predictors. We will built four 
sets of models: (1) nerve function predictor adjusting for age, sex, race, study site, height, and 
weight; (2) Model 1 plus diabetes; (3) Model 2 substituting lean and fat mass for total body 
weight; (4) Model 3 plus other additional confounders related to either the outcome or the 
predictors using an alpha level of 0.1. These additional covariates were then removed from 
Model 4 if they had a p-value >0.1 to prevent collinearity. We also tested the interactions 
between nerve function variables and sex, which were nonsignificant. As a sensitivity analysis, 
we excluded participants with diabetes to test its influence on the associations between nerve 
function and mobility limitation. 
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4.4 RESULTS 
After a median follow-up time of 8.5 (Interquartile Range [IQR]: 4.5-9.6) years from the initial 
nerve exam, 655 (30%) participants developed mobility limitation. Table 4.1 shows the 
characteristics of our study population. Characteristics that bivariately predicted mobility 
limitation included older age, female sex, black race, higher BMI and fat mass, current smoking 
status, diabetes mellitus, cardiovascular disease, cerebrovascular disease, hypertension, low AAI, 
depressive symptoms, and knee and hip pain. Characteristics that were protective for mobility 
limitation included participation at the Pittsburgh study site, alcohol consumption >1/week, 
higher physical activity and better 3MSE and DSST scores. Table 4.2 presents descriptive means 
and frequencies for initial peripheral nerve measures and their bivariate HR predicting mobility 
limitation. Figure 4.2 shows bivariate associations between change in nerve function and incident 
mobility limitation and the number of participants in each nerve change group. 
Tables 4.3 and 4.4 show hazard ratios (HR) and 95% confidence intervals (CI) for initial 
and change in nerve function measures predicting incident mobility limitation. One standard 
deviation lower initial motor amplitude and sustained poor motor amplitude over seven years 
were associated incident mobility limitation when adjusting for all covariates. Declining from 
normal to poor motor amplitude predicted mobility limitation, although was attenuated to 
nonsignificant by lean and fat mass. One standard deviation worse average vibration detection 
threshold was also associated with incident limitation. Both sustained poor and declining to poor 
vibration detection threshold predicted mobility limitation, although they were attenuated to 
nonsignificant when adjusted for diabetes and lean and fat mass, respectively. Initially reporting 
one and two symptoms were associated with mobility limitation. Improving from reporting 2 
peripheral neuropathy symptoms to reporting < 2 also predicted mobility limitation in the 
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minimally adjusted model, but was attenuated to nonsignificant by diabetes. Initially poor 1.4-g 
monofilament sensitivity (10-g sensitivity with 1.4-g insensitivity) was associated with mobility 
limitation, although the association was borderline significant and attenuated to nonsignificant 
when adjusted for diabetes. 
When we excluded individuals with diabetes in the sensitivity analysis, initial lack of 1.4-
g monofilament sensitivity no longer predicted mobility limitation. Initial vibration detection 
threshold was no longer a significant predictor of mobility limitation in the fully adjusted model. 
Transitioning from normal to poor motor amplitude and vibration detection threshold were 
nonsignificant in the minimally adjusted model. All other associations remained consistent with 
the original analysis. 
4.5 DISCUSSION 
Using longitudinal data from a large cohort of older men and women, we quantified the 
relationship between sensory and motor nerve function and incident mobility limitation. Sensory 
and motor nerve function measured at one time point and motor nerve function measured over 
seven years were independent predictors of mobility limitation. Peripheral nerve function is 
understudied in older adults, particularly in those without diabetes, yet our sensitivity analysis 
shows that it is an important predictor of mobility limitation independent of diabetes status. 
These findings have important implications for preventing and delaying mobility disability in 
older adults. More research is needed on developing interventions to target modifiable risk 
factors related to peripheral nerve function and their effect on reducing disability. Secondary 
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prevention of disability in those who have already developed poor nerve function should also be 
investigated. 
One limitation of previous studies is that they have often relied on only one measure of 
peripheral nerve function, usually a sensory measure.27,31 Sensory and motor nerves undoubtedly 
play distinct roles in mobility limitation. Since overt peripheral neuropathy is partially 
characterized through symptoms of weakness and in extreme cases muscle wasting,311 one 
potential mechanism for the relationship between motor nerve function and disability is the 
denervation of muscle fibers. Microscopic examination of muscle tissue in cases of overt 
neuropathy shows smaller atrophied muscle fibers and a shifting from type I slow twitch to type 
II fast twitch fibers due to denervation and reinnervation of muscle fibers.34 These changes 
potentially could lead to decreased muscle strength and power.41 Sensory nerve function 
measures such as monofilament detection and vibration detection threshold, which are also 
cross-sectionally associated with impaired balance, gait, and lower extremity performance,20,331 
may contribute to mobility limitation through loss of proprioceptive feedback.12   
Initial and sustained poor motor amplitude over seven years predicted mobility limitation, 
while motor nerve conduction velocity did not. Previously, we showed that motor amplitude but 
not nerve conduction velocity was cross-sectionally related to poor physical performance and 
quadriceps muscle strength in this same cohort of older adults.21 Low motor amplitude is 
indicative of axonal degeneration and impaired synchronicity of nerve firing, while low nerve 
conduction velocity signifies nerve demyelination.63 These two measures of nerve function may 
not decline simultaneously, since low amplitude may results from axonal damage to a proportion 
of nerves, while normal nerve conduction velocity may persist, driven by the nerves that remain 
intact.33,76 Moreover, the association between mobility limitation and motor nerve amplitude 
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remained the most consistent finding following adjustment for potential confounders. This 
finding suggests that degeneration of the motor axon likely plays a key role in the development 
of mobility limitation. 
Sensory deficits also predicted mobility limitation even though the associations were not 
as robust as those seen with motor function. Associations between mobility limitation and two 
sensory measures, 10-g monofilament sensitivity and vibration detection threshold, were 
attenuated when adjusting for diabetes and nonsignificant in our sensitivity analysis that 
excluded participants with diabetes. This could indicate that poor sensory nerve function is 
particularly important for mobility limitation in individuals with diabetes. Post-hoc analysis 
showed that the interactions between diabetes and vibration detection threshold (HR for 
interaction = 1.23, 95% CI: 1.10-1.38) and diabetes and 10-g monofilament sensitivity (HR for 
interaction = 1.83, 95% CI: 1.32-2.55) were significant predictors of incident mobility limitation, 
indicating greater harmful effects of worse sensory nerve function by diabetes status. 
Strengths of our analysis include that we used multiple measures of sensory and motor 
nerve function, including a gold standard measure of nerve conduction that we found to be 
highly reproducible in a sample of participants from this aging cohort.65 One unique strength is 
that our outcome of incident mobility limitation was assessed semiannually over 10 years 
following the initial measurement of our predictor. Our analysis used prospective data from a 
large well-characterized cohort of older men and women. We assessed nerve function change by 
creating categories from clinically meaningful cut points that allowed for all directions of 
change, including sustained poor function over the seven years and improvement from poor to 
normal. In order to prevent minimal change from biasing our results, individuals with marginal 
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change (< 5%) for continuous measures were not categorized in transitional nerve function 
groups (poor to normal and normal to poor).  
Some groups in the nerve function change analysis did have small numbers, such as the 
poor to normal motor amplitude (n=13) and vibration detection threshold groups (n=17) and the 
sustained poor vibration threshold group (n=13). Low statistical power may have accounted for 
lack of association and attenuation in these groups. Another potential limitation of our study is 
that our participants may have been somewhat healthier than the general population, given that 
they had no mobility limitation at the initial nerve exam. Despite this, we found that 30% of 
participants in the analysis of initial nerve function measures developed mobility limitation. This 
finding illustrates the high incidence of mobility limitation in older adults, and suggests that this 
rate could be even higher in less healthy populations. 
Our findings confirm that peripheral nerve function plays an important role in the 
development of mobility limitation in late-life. The importance of our findings are highlighted by 
the high incidence of mobility limitation that we found in this community-dwelling population of 
older adults and the high prevalence of poor nerve function in older adults.23 It is essential for 
future work to focus on the prevention of nerve function decline and subsequent disability in 
those with poor nerve function through known and novel risk factors.  
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Table 4.1 Participant characteristics as risk factors for mobility limitation 
Characteristics Value HR (95% CI) for mobility 
limitation 
P-value 
Age, years 76.5 (2.9) 1.15 (1.07-1.25) 0.0002 
Women, n (%) 1079 (50.2) 1.18 (1.01-1.37) 0.04 
Black race, n (%) 785 (36.6) 1.25 (1.07-1.46) 0.005 
Pittsburgh site, n (%) 1090 (50.7) 0.64 (0.55-0.75) <0.0001 
Body Composition    
   BMI, kg/m2 27.1 (4.6) 1.29 (1.20-1.39) <0.0001 
   Lean mass, kg 48.3 (10.2) 1.07 (0.99-1.16)  0.07 
   Fat mass, kg 26.5 (8.4) 1.28 (1.19-1.38) <0.0001 
Lifestyle characteristics    
   Current smoker, n (%) 176 (8.3) 1.56 (1.21-2.02) 0.0006 
   Past smoker, n (%) 974 (46.2) 1.05 (0.90-1.23) 0.51 
   Alcohol consumption > 1/week (%) 1103 (52.4) 0.73 (0.63-0.86) <0.0001 
   Physical activity, kcal/kg/week 6.3 (17.5) 0.27 (0.20-0.36) <0.0001 
Chronic conditions    
   Diabetes, n (%) 437 (10.7) 1.63 (1.37-1.96) <0.0001 
   Impaired fasting glucose, n (%) 348 (16.5) 1.02 (0.83-1.25) 0.87 
   Cardiovascular disease, n (%) 344 (17.4) 1.42 (1.16-1.73) 0.0006 
   Cerebrovascular disease, n (%) 126 (6.1) 1.87 (1.42-2.46) <0.0001 
   Hypertension, n (%) 1707 (80.9) 1.66 (1.33-2.08) <0.0001 
   AAI <0.9, n (%) 315 (15.3) 1.60 (1.31-1.96) <0.0001 
   AAI >1.3, n (%) 105 (5.1) 1.32 (0.95-1.84) 0.09 
   Depression, CES-D score 5.4 (5.5) 1.30 (1.22-1.39) <0.0001 
   Osteoporosis, n (%) 76 (3.6) 1.67 (1.18-2.35) 0.004 
   Knee or hip pain, n (%) 445 (21.0)  1.77 (1.50-2.09) <0.0001 
   Low vitamin B12, n (%) 345 (16.8) 1.07 (0.88-1.33) 0.48 
Cognition    
   3MSE score 90.7 (8.0) 0.86 (0.80-0.93) <0.0001 
   DSST score 37.2 (14.5) 0.83 (0.77-0.89) <0.0001 
Data are means ± SD unless otherwise specified; HR are per SD for continuous variables 
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Table 4.2 Peripheral nerve characteristics at year 4 
Peripheral nerve characteristics at Year 4 Value HR (95% CI) for mobility 
limitation 
P-value 
Motor nerve function 
   Amplitude, mV 3.4 (2.0) 1.30 (1.18-1.42) <0.0001 
   NCV, m/s 43.7 (5.3) 1.09 (1.00-1.19) 0.06 
Sensory nerve function 
   Vibration detection threshold 51.2 (35.4) 1.24 (1.15-1.34) <0.0001 
   Monofilament sensitivity 
      10-g, n (%) 1930 (91.6) 0.71 (0.54-0.92) 0.01 
      1.4-g, n (%) 1159 (54.5) 0.81 (0.70-0.95) <0.01 
PN symptoms 
   Pain, n (%) 315 (14.8) 1.92 (1.60-2.31) <0.0001 
   Numbness, n (%) 568 (26.6) 1.58 (1.34-1.86) <0.0001 
   Sores, n (%) 34 (1.6) 1.36 (0.79-2.36) 0.27 
   One, n (%) 735 (34.5) 1.74 (1.49-2.03) <0.0001 
   Two, n (%) 174 (8.1) 2.08 (1.66-2.60) <0.0001 
Data are means ± SD unless otherwise specified; HR are per SD for continuous variables 
Table 4.3 Initial (Year 4) nerve function predicts incident mobility limitation 
HR (95% CI) 
1st Models 2nd Models 3rd Models 4th Models 
Motor nerve function 
   Amplitude per SD lower 1.29 (1.17-1.42)§ 1.29 (1.17-1.42)§ 1.30 (1.17-1.44)§ 1.28 (1.16-1.43)§ 
   NCV per SD lower 1.10 (0.99-1.22) 1.10 (0.99-1.22) 1.10 (0.99-1.23) 1.11 (0.99-1.24) 
Sensory nerve function 
   Vibration per SD higher 1.21 (1.11-1.31)§ 1.18 (1.09-1.29)§ 1.20 (1.11-1.31)§ 1.13 (1.03-1.23)* 
   Monofilament sensitivity 
      None 1.27 (0.96-1.68) 1.24 (0.93-1.65) 1.31 (0.98-1.75) 1.20 (0.86-1.68) 
      10g 1.19 (1.00-1.40)* 1.18 (0.99-1.39) 1.20 (1.01-1.43)* 1.18 (0.98-1.41) 
      1.4g Reference Reference Reference Reference 
Symptoms 
   None Reference Reference Reference Reference 
   One 1.44 (1.21-1.71)§ 1.42 (1.19-1.70)§ 1.44 (1.20-1.73)§ 1.34 (1.10-1.63)† 
   Two 1.44 (1.11-1.86)† 1.41 (1.09-1.82)† 1.44 (1.10-1.87)† 1.42 (1.07-1.88)* 
*P<0.05; †P<0.01; ‡P<0.001; §P<0.0001.
1st Models – adjusted for age, race, height, weight, site 
2nd Models – 1st Models + diabetes 
3rd Models – 2nd Models + lean & fat mass instead of weight 
4th Models:  
Motor nerve function – 3nd Models + arterial stiffening, knee and hip pain, CES-D, smoking, 
alcohol consumption, physical activity, renal function 
Sensory nerve function – 3nd Models + low ankle arm index, cerebrovascular disease, knee and 
hip pain, osteoporosis, CES-D, smoking, physical activity, renal function 
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Symptoms – 3nd Models + low ankle arm index, arterial stiffening, cerebrovascular disease, knee 
and hip pain, CES-D, vitamin B12 status, smoking, alcohol consumption, physical activity, renal 
function 
 
 
 
Table 4.4 Change in nerve function (Year 4 to Year 11) predicts incident mobility limitation 
 Maintained 
Normal 
Normal 
to Poor 
Poor to 
Normal 
Sustained 
Poor 
Motor nerve function  HR 95% CI HR 95% CI HR 95% CI 
     Amplitude REF 2.02* 1.06-3.88 1.94 0.46-8.19 3.56† 1.63-7.76 
     NCV REF 1.75 0.90-3.40 1.73 0.72-4.17 1.97 0.94-4.16 
Sensory nerve function        
     1.4g  monofilament  
     sensitivity 
REF 1.06 0.64-1.75 1.40 0.86-2.29 1.17 0.73-1.89 
     10g monofilament  
     sensitivity 
REF 1.52 0.94-2.44 1.07 0.39-2.94 0.56 0.17-1.80 
     Vibration threshold REF 1.99* 1.11-3.59 2.45 0.96-6.25 2.90* 1.16-7.24 
2 Symptoms REF 1.94* 1.13-2.77 1.13 0.46-2.77 1.15 0.42-3.13 
Model adjusted for age, sex, race, site, height, weight, and weight change; 
Poor nerve function defined as <1 mV for motor amplitude, <40 m/s for velocity, lack of 
detection of 3 out of 4 touches with 1.4-g and 10-g monofilaments, lack of detection of >131 µ 
of vibration, reporting 2 or more peripheral neuropathy symptoms. 
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 Figure 4.1 Participants in analysis 
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Figure 4.2 Bivariate associations between change in nerve function and mobility limitation 
*P<0.05; †P<0.01; ‡P<0.001; §P<0.0001;
Poor nerve function defined as <1 mV for motor amplitude, <40 m/s for velocity, lack of 
detection of 3 out of 4 touches with 1.4-g and 10-g monofilaments, lack of detection of >131 µ 
of vibration, reporting 2 or more peripheral neuropathy symptoms. 
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5.0  DISCUSSION 
5.1 SUMMARY OF FINDINGS 
The results of our analyses show that sensory and motor peripheral nerve function are associated 
with muscle power, longitudinal quadriceps strength, and mobility limitation in older adults. 
Findings from the MrOS study indicate that, in men, poor motor and sensory nerve function are 
independently associated with lower muscle power and that light monofilament insensitivity is 
associated with greater decline in muscle power. This was the first study to examine the cross-
sectional and longitudinal associations between nerve function measures commonly used in 
clinical evaluations and neurologic studies and muscle power. Prior to this, it was generally 
accepted that decline in power was at least partly due to loss of peripheral nerve function with 
age, although the association between these two measures had not been tested even at a cross-
sectional level. In addition, we presented the effect sizes of our nerve function predictors in 
terms of the effect of age and found that they were 1.5 to 3.5 times higher than one year of age. 
These findings contextualize the relationship between nerve function and power, since muscle 
power in known to decline with age at an even faster rate than strength,69,70 though strength has 
been more widely studied in aging research. Since our study was limited to mostly white men, 
future studies should examine these relationships in more diverse study populations of men and 
women. Our follow-up time for our longitudinal analysis was only 2.3 years, therefore the 
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longitudinal relationships between nerve function and muscle power over a longer time period 
should be investigated. In addition, other methods of measuring power should be assessed since 
they vary by intensity of activity, availability of data, and the force-velocity ratio that comprises 
power.  
Using prospective data from the Health ABC Study, we found that, in women, poor 
motor and sensory nerve function predicted lower subsequent strength and that poor sensory 
nerve function predicted greater strength decline. In men, however, only poor sensory nerve 
function predicted lower subsequent strength. When assessing concurrent change, sustained poor 
sensory nerve function, initial poor motor nerve function and monofilament sensitivity, and 
transitioning to poor vibration perception threshold were associated with lower longitudinal 
strength. This work is important because this was the first study to use prospective data to show 
that sensory and motor nerve function are predictive of subsequent strength and concurrent 
change in strength, indicating that poor nerve function may be an important mechanism for poor 
and declining strength in older adults. Because we used data from a large cohort of men and 
women, we were also able to identify sex as a modifier in the relationship between nerve 
function and longitudinal strength. These sex differences are important because they could shed 
light on differences in risk factors and disability outcomes between men and women. Moreover, 
they could suggest a need for interventions for specific impairments targeted towards each sex. 
Future work should further investigate these sex differences. Because we had small numbers in 
groups for the nerve function change analysis, these results should be confirmed in a larger 
population. In addition, we only measured nerve function change at two time points, seven years 
apart. Future studies should examine multiple time points to better characterize the timing of 
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peripheral nerve function and strength decline and the effect of the duration of poor nerve 
function. 
Once again, we used prospective data from the Health ABC study, this time with the goal 
of assessing the relationship between sensory and motor peripheral nerve function and mobility 
limitation. We found that 30% of our study population had incident mobility limitation. This is a 
staggering proportion and likely underestimates the rate experienced by the general population 
given that these participants were healthy at baseline and had to visit the clinic for a nerve exam 
during the 2000/01 study year. Poor initial motor and sensory nerve function and sustained poor 
motor nerve function over seven years independently predicted incident mobility limitation. This 
was the first study to use multiple measures of nerve function to examine the longitudinal 
relationship between motor nerve function and incident mobility limitation in cohort of both men 
and women. In addition, the majority of research had been cross-sectional and focused on 
performance measures20,27 or was limited to moderately to severely disabled women.27,31 These 
findings are significant since they suggest that future work targeting modifiable risk factors for 
peripheral nerve function may be important for disability prevention. Secondary prevention of 
disability in those who already have poor nerve function is also an important future direction. 
Moreover, we found that these associations persisted when adjusting for known risk factors such 
as diabetes mellitus and poor vitamin B12, suggesting that novel risk factors should be explored. 
5.2 PUBLIC HEALTH SIGNIFICANCE 
There is a high incidence and prevalence of poor nerve function and overt neuropathy in older 
adults both with and without diabetes mellitus.22,23 Many adults experiencing poor nerve function 
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may be asymptomatic and unaware of persisting pathology. Our findings indicate that poor initial 
motor and sensory nerve function may lead to lower strength, power, and greater incidence of 
mobility limitation anywhere from two to seven years later. We found evidence of improvement 
from poor to normal nerve function, yet this was not always accompanied by better muscle 
function; this suggests that although nerve function improvement is possible, the effect on 
muscle function and disability may persist. Therefore, future work should not only focus on 
interventions for modifiable risk factors of neuromuscular impairment, but also on administering 
those interventions early enough to have an effect. Light (1.4-g) monofilament insensitivity was 
predictive of greater muscle power decline. Future works should examine whether this simple 
test can be used as a screener to identify those who may be at risk for muscle power decline and 
whether it should be included as part of routine geriatric assessment. In addition, understanding 
the role of neuromuscular parameters in the disablement process may help to identify multiple 
points of intervention. The effects of known risk factors for poor nerve function such as diabetes 
and vitamin B12 deficiency and novel risk factors should be studied on muscle function and 
ultimately on mobility disability. In addition, interventions targeted at increasing muscle strength 
and power should be investigated in individuals with poor and at risk for poor peripheral nerve 
function, with the goal of preventing subsequent disability. 
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